Graduate Theses, Dissertations, and Problem Reports
2022

ERO1α
ERO1 Promotes Tumorigenesis in EGFR Driven NSCLC
brennan d. johnson
West Virginia University, bdj0003@mix.wvu.edu

Follow this and additional works at: https://researchrepository.wvu.edu/etd
Part of the Biochemistry Commons, Cancer Biology Commons, Pharmaceutics and Drug Design
Commons, and the Structural Biology Commons

Recommended Citation
johnson, brennan d., "ERO1α Promotes Tumorigenesis in EGFR Driven NSCLC" (2022). Graduate Theses,
Dissertations, and Problem Reports. 11621.
https://researchrepository.wvu.edu/etd/11621

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

ERO1α Promotes Tumorigenesis in EGFR Driven NSCLC
Brennan Dakota Johnson

Dissertation submitted to the School of Medicine
at West Virginia University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy
in
Cancer Cell Biology

Werner Geldenhuys, PhD, Chair
Scott Weed, PhD
Mike Ruppert, PhD
Aaron Robart, PhD
Elena Pugacheva, PhD
Lori A Hazlehurst, PhD, Mentor

Cancer Cell Biology PhD Program,
Morgantown, West Virginia
2022
Keywords: Lung Cancer, EGFR, ERO1α, Redox, Flavoenzyme

Copyright 2022 Brennan Dakota Johnson

ABSTRACT
ERO1α Promotes Tumorigenesis in EGFR Driven NSCLC
Brennan Dakota Johnson
Non-Small Cell Lung Cancer (NSCLC) is a pulmonary malignancy most commonly associated with
smoking, or exposure to asbestos or Radon. Approximately, 1.6 Million deaths occur each year due to
lung cancer. Lung Cancer is categorized by two main types, Small Cell Lung Cancer (SCLC) and
NSCLC. NSCLC accounts for approximately 85% of all lung cancer cases and is subdivided into three
sub-categories: Adenocarcinoma, the most common and leading cause of death in the United States;
Squamous Cell Carcinoma (SCC), and Large Cell Carcinoma. Though NSCLC treatment regimens have
shown increasing clinical benefit over the last two decades with targeted therapies. Emergence of
resistance still remains a clinical obstacle. Endoplasmic reticulum oxidoreductase-1α (ERO1α) is a flavin
adenosine dinucleotide (FAD) containing enzyme (flavoenzyme) that has been shown to be a poor
prognostic indicator in multiple cancer types. ERO1α is responsible for folding secretory and
transmembrane proteins through disulfide bond formation in conjunction with protein disulfide isomerase
(PDI). However, ERO1α has also been shown to form de novo disulfide bridges. ERO1α contributes
directly to protein folding through redox reactions that occur between the reactive cysteine bridges (Cys94-Cys99, and Cys394-Cys397) within ERO1α by which electrons are shuttled from PDI onto ERO1α at
Cys94-Cys99, then shuttled onto Cys394-Cys397, followed by transfer of electrons on the FAD ring at
which time Molecular oxygen is used as a terminal electron acceptor to produce hydrogen peroxide.
Hydrogen peroxide can then be eliminated by peroxidases and other enzymes to reduce ER stress.
Proper protein folding is required to maintain homeostasis within the endoplasmic reticulum. Here, we
identify ERO1α as novel target for targeted therapy in NSCLC and propose ERO1α clonogenicity and
tumorigenecity through oxidative folding of LAMC2.
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CHAPTER 1.1.0: Lung Cancer Overview and Classification
Lung cancer is separated into two main types: Non-Small Cell Lung Cancer (NSCLC) and Small Cell
Lung Cancer (SCLC). Lung cancer is the second most common type of cancer and leading cause of
cancer deaths worldwide, and despite having multiple treatment modalities the overall five-year survival
for patients with lung cancer is only 7% for all SCLC stages combined and only 26% for all NSCLC
stages combined1, 2. Thus, the clinical data indicates that new treatment strategies including identification
of novel targets are needed to improve patient outcomes. Validation of a target includes strategies to
genetically manipulate the expression levels and determine effects on pathology in vivo and differences
in phenotype across NSCLC cell lines. In addition, pharmacological validation of the target is required to
understand the potential therapeutic window of the putative chemotherapeutic strategy. This thesis aims
to determine whether targeting ERO1α is a tractable strategy for further pre-clinical development for the
treatment of lung cancer.
NSCLC:
NSCLC compromises approximately 80-85% of all lung cancers and can be separated into the three
distinct subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma1, 2. The subtypes
often arise from different types of lung cells but are grouped together as NSCLC as treatment and
prognosis are often similar. Adenocarcinoma is the most common subtype of NSCLC and arises from
cells that normally secrete mucus. This subtype of lung cancer occurs mainly in people who smoke or
have quit smoking. Interestingly, it is also the most common type of lung cancer even in people who do
not smoke or have never smoked1, 2. Typically found within the outer regions of the lung, adenocarcinoma
is also likely to be found before it has metastasized and thus these patients tend to have a better
prognosis than other types of lung cancer2. Lung adenocarcinoma still remains as the leading cause
1

cancer deaths in the United States3. Furthermore, lung adenocarcinoma is classified into 4 subtypes:
Adenocarcinoma in situ (AIS), minimally invasive adenocarcinoma (MIA), invasive adenocarcinoma, and
variants of adenocarcinoma3. Of these subtypes, AIS and MIA have better outcomes when resected
early3. Local spread of lung adenocarcinoma may spread directly into the pleura, diaphragm,
pericardium, or bronchi with advanced disease spreading to the mediastinum, great vessels, trachea,
esophagus, vertebral column, or adjacent lobe’(s)1, 3. Lymph node metastasis occurs in peribronchial
lymph nodes before moving into mediastinal or subcarinal nodes and then the contralateral lung. Distant
metastasis includes an extension to a contralateral lobe, pleural nodules, malignant pleural, pericardial
effusion, or any distant site such as brain, bones, and/or liver3, 6, 7. A subset of NSCLC adenocarcinoma
that have mutations in epidermal growth factor receptor (EGFR), which sensitizes them to tyrosine kinase
inhibitors (TKI’s), as well as anaplastic lymphoma kinase (ALK) fusion oncogene rearrangements7, 8.
Squamous cell carcinoma (SCC) originates from squamous cells. These are the flat cells that line the
inside of the airways of the lungs and are often linked to a history of smoking and are typically found
within the central part of the lungs near the main bronchi2. SCC is the second most common subtype of
NSCLC, and is often associated with patterns of tobacco smoke9. Transformed SCC is characterized by
keratinization and/or intercellular bridges and often exhibits a high degree of mutation frequency10. Large
cell (undifferentiated) carcinoma (LCC) can appear in any part of the lung. This subtype tends to grow
and spread quickly, making it more difficult to treat1, 2. LCC typically presents as large, peripheral,
necrotic masses that invade adjacent tissues and structures1, 2.
SCLC:
Small Cell Lung Cancer only accounts for ~10-15% of all lung cancers. SCLC tends to grow and
metastasize faster than NSCLC2. SCLC has been shown to harbor a bi-allelic inactivation of p53 and
RB1 in almost all examined SCLC samples11. About 70% of all patients diagnosed with SCLC will have
2

disease that has spread and the time of diagnosis2. Due to its fast-growing nature, SCLC tends to
respond well to chemo- and radiation therapy. However, despite responding well to therapies, most
patients will relapse with recurrent disease1, 2. Accounting for all SCLC cases and stages, the overall
survival rate is ~7%1.
1.1.1 Common Oncogenic Drivers/Mutations
Lung cancer as mentioned above is separated into two main categories, SCLC and NSCLC. SCLC
typically does not have a high mutation burden or known oncogenic drivers to the same frequency as
NSCLC. There are many known mutations and/or oncogenic drivers in NSCLC. These include mutations
in EGFR, KRAS, ALK, MEK, and PI3K, amongst others. Of the mutations mentioned EGFR and KRAS
are the most abundant mutations found in patients diagnosed with NSCLC. Below a breakdown of the
mutations found within EGFR and KRAS will be discussed in detail, along with how these mutations can
alter treatment regimens.
EGFR:
Epidermal Growth Factor Receptor (EGFR) belongs to the ERBB family of receptor tyrosine kinases
(RTK’s). ERBB family of RTK’s consist of EGFR (ERBB1, HER1), HER2 (ERBB2, neu), HER3 (ERBB3)
and HER4 (ERBB4). The ERBB family of RTKs was first implicated in cancer in the early 1980s when it
was discovered that EGFR had high sequence homology with avian erythroblastosis tumor virus (AEV)12,
13.

Each member of the ERBB family is composed of an extracellular ligand-binding domain, a single

transmembrane domain, and an intracellular domain which includes the tyrosine kinase 14 domain15.
EGFR signaling is typically initiated when a ligand binds to the ectodomain, causing a conformation
change allowing for homo- or hetero-dimerization to occur with other ERBB family members. This
dimerization activates cytoplasmic catalytic activity resulting in trans- and autophosphorylation of tyrosine
3

residues in the cytoplasmic tails which serve as docking sites for several adaptor proteins that can initiate
signaling cascades16. Ultimately, resulting in deregulated cell proliferation, cell survival, angiogenesis,
and metastasis15. EGFR is amongst the most frequently mutated genes in NSCLC. The selective
response of NSCLC patients to EGFR tyrosine kinase inhibitors (TKI’s) such as gefitinib and erlotinib
allowed for the identification of oncogenic EGFR mutations17-20. Most associated mutations with EGRF
are activating mutations that occur within the catalytic kinase domain exons (18-24), including small inframe deletions found at amino acids 747-750 of exon 19, and the L858R mutation occurring at exon 21.
In frame deletion at exon 19 and the missense mutation occurring in exon 28 resulting in L858R are
amongst the most common EGFR activating mutations found in patients, and these patients typically
respond well to 1st or 2nd generation TKI’s gefitinib and or erlotinib18, 20, 21. Lastly, despite patients
harboring L858R or exon 19 in-frame deletion responding well to TKI’s at first, relapse generally occurs,
and patients are resistant to originally therapy. The resistance mechanism to erlotinib and other EGFR
TKIs has been well described and is generally from the development of the EGFR missense mutation in
exon 20 that results in T790M22-25. The T790M mutation structurally corresponds to the mutated
gatekeeper residue T315I in BCR-ABL, T679I in c-KIT, and T674I in PDGFRα and results in an increased
affinity to ATP, resulting in decreased sensitivity to ATP- competitive reversible inhibitors26, 27. While
T790M missense mutation is one of the most frequently found mutations in EGFR, it is very rare in drugnaïve primary patient samples and unrelated tumors but is the most common in patients who have
relapsed following treatment with EGFR TKI’s 14, 19, 27. Afatinib is a second-generation EGFR irreversible,
covalently bound inhibitor more recently approved for the treatment of EGFR activating mutations, but still
has decreased sensitivity to tumors harboring the T790M mutation 22, 25. However, in 2015 Osimertinib,
based on a pyrimidine scaffold that forms a covalent bond with Cys797 at the edge of the ATP binding
pocket, received fast-track designation by FDA for patients harboring T790M mutation, and even showed
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promising efficacy as a first-line treatment for EGFR activating mutations in NSCLC23, 28. These most
common EGFR mutants as described can be seen in Figure 1.

Figure 1: Schematic depicting common EGFR (ERBB1) mutations in NSCLC patients, type, as well the domain and
exon location at which each mutation occurs.

These activating mutations are clustered around the ATP binding pocket of EGFR and can display up to
50-fold acceleration in the catalysis of ATP by disrupting the autoinhibitory interactions29, 30. This
disruption of the autoinhibitory feedback loop results in an increase in pro-survival and anti-apoptotic
signals via activation of downstream targets including PI3K-AKT, ERK, and STAT1/3. Thus, these
resulting mutations represent classical cases of oncogene addiction 15, 31. Despite more than 70 known
mutations found within EGFR, there are only approved targeted therapies for three mutations out of thr
70 that is known; however, recent data suggests the current inhibitors are also efficacious at targeting the
other EGFR mutants in a clinical setting.16, 32, 33.
KRAS:
KRAS is amongst one of the most highly mutated genes within NSCLC. KRAS stands for Kirsten Rat
Sarcoma viral oncogene homolog. KRAS gene provides instructions for making the protein K-Ras and is
part of downstream signaling from the EGFR pathway, it is also part of the RAS/MAPK signaling
pathway. K-Ras mutations are the most common oncogenic mutation in all human cancers and were
5

thought to be an undruggable target34. The Ras family encodes for 3 small enzymes (KRAS, NRAS,
HRAS) that hydrolyze guanosine triphosphate (GTPase), linking upstream cell surface receptors such as
EGFR, FGFR, and ERBB2-4 to downstream proliferation and survival pathways such as RAF-MEK-ERK,
PI3K-AKT-mTOR, and RALDGS-RA35. KRAS mutations occur in 20-40% of adenocarcinomas, and their
prevalence is higher in western populations vs Asian populations (26% vs 11%) and smokers vs nonsmokers (30% vs 10%)36. The most frequent KRAS mutations occur in codons 12 and 13, with the most
common subtypes including G12C, G12V, and G12D37. Other genes such as TP53 (40%), STK11 (32%),
and CDKN2A (19.8%) are frequently found to be co-mutated with KRAS37. These subgroups tend to be
mutually exclusive and seem to have no contextual preference between KRAS mutant alleles38-42.
Despite knowledge surrounding KRAS mutants such as G12x (where x can be C, V, or D) targeting
KRAS mutant lung cancer has shown little success until recently. However, originally three main
approaches were taken towards targeting KRAS. First, failed trials of farnesyl transferase inhibitors were
abandoned upon discovery that KRAS and NRAS could employ geranyl-geranylation as an alternative
mechanism to farnesylation activation of oncogenic KRAS43-45. Secondly, downstream inhibition of MEK
using selumetinib in combination with docetaxel failed to show significant improvements in survival or
response, this was repeated with trametinib in combination with docetaxel46-48. Finally, several synthetic
lethality screens were performed using KRASm NSCLC identifying BCL-XL, TANK binding kinase-1, and
CDK449-53. The main hit that came from these studies was CDK4 inhibitor abemaciclib and was employed
as an inhibitor in phase I-III clinical trials of KRASm disease setting in NSCLC, but results thus far are not
encouraging54. However, after decades of trying to target KRAS directly, the first KRAS inhibitor has
received FDA fast-track designation for advanced and/or relapsed NSCLC patients harboring mutant
KRAS (G12C) and have a previous systemic therapy on May 28, 2021. Lumakras (sotorasib) is a first-inclass covalent inhibitor directed toward targeting KRAS mutant G12C55 and is made and produced by
6

AMGEN. Thus, KRAS can now be seen as an actionable target and more studies need to be done to
determine if the other KRAS mutants can also be targeted with sotorasib, or if other inhibitors should be
developed.
Despite EGFR mutations being actionable in the clinic with multi-generational tyrosine kinase inhibitors
(TKIs), the emergence of resistance to these TKIs remains a problem for the treatment of NSCLC.
Therefore, the need for new targeted therapies and the identification of actionable targets is needed.
Recently, there have been multiple reports on endoplasmic reticulum oxidoreductase-1α (ERO1α)
indicating its’ role in multiple cancer types; including lung adenocarcinoma56.
1.1.2 Protein Folding and ERO1α
The endoplasmic reticulum (ER) is a major protein folding compartment for the secreted, plasma
membrane, and organelle proteins57. Interestingly, most ER resident proteins are dedicated to the protein
folding process58. The order of events by which all protein modifications occur alongside folding was
originally predicted to occur in the following order: Translation→Folding→ N-Linked Glycosylation→
Signal peptide cleavage→ disulfide bond formation→ Pro-isomerization→ Oligomerization→ Exit from
ER57-59. In actuality, many of these steps are happening in parallel simultaneously58, 59. One of the largest
reasons this has to happen in parallel is due to the high concentration of proteins within the ER during the
folding process. The high protein content of unfolded proteins subjects them to aggregation if the folding
and modification process does not happen quickly and concisely58, 59. To ensure proper protein folding
occurs within the ER, molecular chaperones are present. Chaperones belonging to the Heat Shock
Protein family (Hsps), reside next to the lectin chaperones that recognize a specific glycan composition of
the protein to be folded58, 59. No chaperone works alone. Hsps, are responsible for coupling client-binding
cycles to ATPase cycles, which are regulated by functional classes of co-chaperones, whereas the
7

carbohydrate chaperone team up with a set of enzymes that support the functioning chaperone cycle.
Folding enzymes catalyze disulfide bond formation or proline cis-trans isomerization, both essential for
physiological folding58.
Protein Processing and Modification
Most proteins are co-translationally targeted to the ER by signal sequences, which are commonly found
within the first 25 amino acids of the nascent polypeptide58, 59. Signal sequences are comprised of an
amino-terminal basic domain (N-domain), a medial hydrophobic domain (H-domain), and a polar domain
that contains the cleavage site (C-domain)60. The N- and H-domains help position the peptide in a looped
orientation during translocation with the N-domain facing the cytoplasm, the H-domain in the core lipid
bilayer, and the C-domain facing the ER lumen for recognition and cleavage by the signal peptidase
complex (SPC)58, 59. The nature of the signal sequence can affect the efficiency of targeting and timing of
cleavage, ultimately, affecting the following maturation steps57-59.
Most proteins that traverse the eukaryotic secretory pathway are modified by N-linked glycans on
asparagine residues found in the Asparagine-X-Serine/Threonine sequence57-59. This modification is
frequently added co-translationally once the protein reaches ~13 amino acids deep in the ER lumen,
aligning the modification site at the asparagine residue with the active site of the
oligosaccharyltransferase (OST)61. The hetero-oligomeric transferase complex transfers a preassembled
carbohydrate comprised of three glucose, nine mannoses, and two N-acetyl glucosamines to the
asparagine residue58. It is important to note that rapid folding and oxidation of a protein can diminish the
level of glycosylation62. Glycosylation of proteins has both intrinsic and extrinsic effects on the stability
and conformation of a protein58, 59. An extrinsic effect includes the recruitment of carbohydrate-binding
factors in the ER lumen and influences the maturation and sorting of the nascent chain, and an intrinsic
8

effect includes the addition of a bulky hydrophobic carbohydrate which directly alters the inherent
physical properties of the protein. N-linked glycosylation has been shown to improve both kinetics and
thermodynamics of folding for isolated proteins; however, it can also increase the stability of proteins by
masking hydrophobic stretches, proteolytic cleavage sites, or immune recognition 63-65.
The ER houses several molecular chaperones that are dedicated to the proper maturation and sorting of
maturing nascent chains in the early secretory pathway58. There are two main types of molecular
chaperones found within the ER: the classical chaperones and the carbohydrate-binding chaperones58.
The classical chaperone system is found in almost all cellular locations and generally involves Hsps that
bind directly to the polypeptide chain. In contrast, the carbohydrate-binding system is found solely in the
ER and involves interactions with the hydrophilic glycan modification (glycosylation)58, 59. Together, these
two systems work to ensure that protein flux through the ER is maintained properly for a large variety of
proteins that require traversing the secretory pathway.
The ER also contains multiple folding enzymes. These enzymes do not influence the final equilibrium of a
reaction but instead work as catalysts to increase the rate at which equilibrium is reached58, 59. There are
two main classes of ER folding enzymes: Oxidation-reduction and Proline isomerization. Both these
classes act as a catalyst, and the direction of the reaction is determined by environmental conditions
such as the redox state by the folding protein, and by the driving forces of folding, which include burial of
the hydrophobic residues in a soluble protein, formation of hydrogen bonds, and electrostatic
interactions57-59. Protein Disulfide Isomerase (PDI) was the first discovered and best-characterized
oxidoreductase in the ER66. Dependent on conditions, it catalyzes formation, isomerization, or reduction
of disulfide bonds and is considered to have broad substrate specificity58. In lower eukaryotes such as
yeast, a single protein (ERO1α) is both necessary and sufficient to catalyze disulfide bond formation in
PDI67. ERO1α is an endoplasmic reticulum resident oxidoreductase that undergoes redox with Protein
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Disulfide Isomerase (PDI) to aid in the folding of transmembrane and secretory proteins 68-70. ERO1α also
has the capability of forming De Novo disulfide bridging, aiding in the formation of proper tertiary folding
structures of target proteins meant for the plasma membrane and secretory proteins 68, 69. PDI will accept
electrons from a substrate, by which ERO1α can then accept the electrons from PDI, shuttle them
through its’ two disulfide bridges, then onto flavin adenine dinucleotide, by which electrons are then
placed onto molecular oxygen to form hydrogen peroxide: ultimately regenerating ERO1α for another
round of catalysis67. The main difference between yeast and mammals is that mammals contain two
isoforms of ERO1L: ERO1α and ERO1β that seem to have similar functions but differ in tissue
distribution68, 71. In both yeast and mammals, the primary enzyme oxidized by ERO1α is PDI itself,
although other PDI family members may be substates70. It is also important to note that glutathione is a
very poor substrate for ERO1α, and thus PDI can be oxidized even in the presence of relatively high
concentrations of glutathione72. This segregation provides a rationale for how oxidation of PDI can still
occur in the presence of a reductive pathway67. Without oxidoreductase capability in the ER, protein
folding would be too slow and prone to aggregation and degradation67. Considering that protein folding
occurs spontaneously and that chaperones are guides, the formation of nonnative disulfide bonds during
folding is crucial67.
According to The Human Protein Atlas (HPA), ERO1α is ubiquitously expressed in most tissues but was
found to have increased expression in certain tissues such as the brain, lung, and female reproductive
tissues. Recent reports suggest that ERO1α promotes proliferation and cell cycle progression in
cholangiocarcinoma73, promotes breast cancer colonization of the lung and increased overall tumor
burden74-77, promotes metastatic burden through IL-6, and increases angiogenesis in lung
adenocarcinoma56, 78. Increasing reports are revealing that ERO1α promotes tumorigenesis and
metastasis, however, the mechanism(s) underpinning how ERO1α promotes tumorigenesis and
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metastasis remains unclear. Knowing that ERO1α aids in the folding and secretion of secretory proteins,
we hypothesize that ERO1α is promoting tumorigenesis and metastasis by aiding in the secretion of
extracellular matrix proteins (ECM), as a previous report suggests a deficiency in oxidoreductase activity
in the secretory pathway results in ECM deficiencies79.
1.1.3 Extracellular Matrix and Laminins
The Extracellular matrix (ECM) is the non-cellular component that attaches cells to the basement
membrane and is present in all organs and tissues80. It provides essential physical scaffolding for its’
cellular constituents and also initiates crucial biochemical and biomechanical cues that are required for
morphogenesis, differentiation, and homeostasis80. The importance of ECM stability is vividly
demonstrated by the wide range of syndromes that arise from genetic abnormalities within ECM
proteins80, 81. Fundamentally, the ECM is composed of water, proteins, and polysaccharides80,81.
However, each tissue has its own unique ECM, and ECM can even vary within the same tissue80. ECM
formation occurs dynamically and reciprocally, with biochemical, and biophysical crosstalk occurring
between cellular components (epithelial, fibroblast, adipocyte, endothelial elements) and the evolving
cellular and protein microenvironment80. The physical, topological, and biochemical composition of the
ECM is not only tissue-specific but also heterogeneous. Cell adhesion to the ECM is mediated by ECM
receptors, such as integrins, discoidin domain receptors, and syndecans82-85. Adhesion mediates
cytoskeletal coupling to the ECM and is involved in cell migration86. Moreover, the ECM is a highly
dynamic structure that is constantly being remodeled; either enzymatically or non-enzymatically80.
Through these physical and biomechanical properties, the ECM generates tissue-specific properties for
each organ, such as its tensile strength and elasticity.80 Amongst being responsible for tensile strength
and elasticity, the ECM is also responsible for protection via buffering action that maintains extracellular
homeostasis and water retention.80 In addition, the ECM directs the essential morphological organization
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and physiological function by binding growth factors (GF) and interacting with cell-surface receptors to
elicit signal transduction and regulate gene transcription80. The ECM’s biomechanical and biochemical
properties can differ greatly from tissue to tissue as well as from one physiological state to another80. The
two main classes of macromolecules that compose the ECM are the proteoglycans (PG) and fibrous
proteins81, 87, 88. The main fibrous proteins are collagens, elastins, fibronectins, and laminins80,81.
Interestingly, publicly available mass spectrometry data of lung adenocarcinoma samples (CPTAC)
revealed through a Pearson correlation that four genes (LAMB3, LAMC3, FN, and COL7A1) protein
expression correlated with ERO1α expression as shown in Figure 2A, B.

Figure 2: Pearson Correlation On Publicly Available CPTAC Data Reveals Fibrous ECM Proteins Correlate
With ERO1α Expression In Lung Adenocarcinoma Patients. A.) Pearson correlation of CPTAC data to
determine genes that correlated with ERO1α expression. B.) Top genes that correlated with ERO1α expression.

Interestingly, these four genes belong to the fibrous family of proteins that are found within the ECM
(laminins, collagen, and fibronectin). To date, 28 types of collagen have been identified, and the majority
of collagen molecules form triple-stranded helices that subsequently can assemble into supramolecular
complexes such as fibrils and networks80, 89. Fibrous collagens form the backbone of the collagen fibril
bundles within the interstitial tissue stroma, whereas network collagens are incorporated into the basal
12

membrane (BM)80, 89. Collagen synthesis involves multiple post-translational modifications; mainly
hydroxylation of proline and lysine residues, glycosylation of lysine residues, and the cleavage of N- and
C-terminal propeptides89. Upon cleavage, collagen fibrils are strengthened through covalent crosslinking
of lysine residues within neighboring collagen fibrils by lysyl oxidases (LOX)90, 91, which were also found
to correlate with ERO1α expression in Figure 2 (LOXL2 and PLOD2). Fibronectin (FN) is secreted as a
dimer joined by two C-terminal disulfide bonds and contains multiple binding sites for other FN dimers,
collagen, heparin, and cell surface integrin receptors92. Cell surface binding of soluble FN dimer is
essential for its assembly into longer fibrils. Moreover, cell contraction through the actomyosin
cytoskeleton and the resulting integrin clustering promotes FN-Fibril assembly by exposing cryptic
binding sites thus allowing them to bind one another93-95. FN is intimately involved in directing the
organization of the interstitial ECM, and additionally, has a crucial role in mediating cell attachment and
function80. Lastly, laminins are large molecular weight glycoproteins constituted by the assembly of three
disulfide-linked polypeptides: the α, β, and γ chains96. The human genome encodes 11 genetically
distinct chains. Structurally, laminin chains differ by the number, size, and organization of a few
constitutive domains, allowing for each laminin to have its’ own unique properties96. Laminins are large
molecular weight building blocks that bridge intracellular and extracellular compartments while relaying
signals that are critical for cellular behavior, and for extracellular polymers that aid in the architecture and
physiology of basement membranes96. Laminins have been linked to cancer since the late 1970s, when a
large molecular weight (~850kDa) non-collagenous glycoprotein was isolated from the basement
membrane-rich tumor transplantable to mouse (EHS sarcoma) and basement membrane producing
cells97, 98. This protein was purified and underwent biochemical characterization and was later given the
name laminin97, 98. Later, similar material was identified in various tissues and cells, thus revealing
“laminin” from EHS was not unique but part of a larger family99, 100. The early discovery of laminins led
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researchers to conclude that it was the main cell adhesion molecule101. Further dissection of laminin 111
from EHS sarcoma via pepsin treatment revealed several binding sites. The first fragment P1 obtained by
pepsin treatment promoted cell adhesion activity and originated in the cross. The second fragment
revealed additional non-cryptic cell binding sites that were present on the short arms and were found to
be ligands for the α1β1 and α2β1 integrins, while the other fragments from the long arm revealed to have
either heparin-dependent (E3) or independent (E8) cell binding activity102, 103. Laminin was finally
classified by the independent chains it contains and determined the collagen and integrin binding
domains were always located within the β-chains, while the heparin-dependent or independent binding
domains were always on the α-chains96. Interestingly, two laminin chains were found to correlate with
ERO1α expression in Figure 2 (LAMB3 and LAMC2). Although LAMB3 is found in multiple laminin
trimers, LAMC2 is specific for Laminin-332 (formerly known as laminin-5) and contains 3 EGF-like
domain repeats96. Although LAMC2 is only found within laminin-332, there are also increasing reports
that it has cancer-promoting properties including increasing overall clonogenicity in pancreatic ductal
adenocarcinoma (PDAC) and promoting tumorigenicity in lung adenocarcinoma as a soluble monomer.
Taken together, the publicly available data suggest that LAMC2 and other ECM proteins are associated
with ERO1α expression, and that these ECM proteins such as LAMC2 can promote tumorigenesis. Thus,
here we aim to demonstrate that ERO1α expression promotes secretion of LAMC2 and that ERO1α is a
novel target for the treatment of EGFR-driven NSCLC.
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2.1.1 Abstract:
Endoplasmic reticulum oxidoreductin-1 alpha (ERO1α) was originally shown to be an endoplasmic
reticulum (ER) resident protein undergoing oxidative cycles in concert with protein disulfide isomerase
(PDI) to promote proper protein folding and to maintain homeostasis within the ER. ERO1α belongs to
the flavoprotein family containing a flavin adenine dinucleotide utilized in transferring of electrons during
oxidation-reduction cycles. This family is used to maintain redox potentials and protein homeostasis
within the ER. ERO1α’s location and function has since been shown to exist beyond the ER. Originally
thought to exist solely in the ER, it has since been found to exist in the golgi apparatus, as well as in
exosomes purified from patient samples. Besides aiding in protein folding of transmembrane and
secretory proteins in conjunction with PDI, ERO1α is also known for formation of de novo disulfide
bridges. Public databases, such as the Cancer Genome Atlas (TCGA) and The Protein Atlas, reveal
ERO1α as a poor prognostic marker in multiple disease settings. Recent evidence indicates that
ERO1α expression in tumor cells is a critical determinant of metastasis. However, the impact of
increased ERO1α expression in tumor cells extends into the tumor microenvironment. Secretory
proteins requiring ERO1α expression for proper folding have been implicated as being involved in
immune escape through promotion of upregulation of programmed death ligand-1 (PD-L1) and
stimulation of polymorphonuclear myeloid derived suppressor cells (PMN- MDSC’s) via secretion of
granulocytic colony stimulating factor (G-CSF). Hereby, ERO1α plays a pivotal role in cancer
progression and potentially immune escape, making ERO1α an emerging attractive putative target for
the treatment of cancer.
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2.1.2. Introduction:
The failure to eradicate minimal residual disease often located at metastatic sites and/or the bone
marrow niche continues to be a clinical barrier for successful treatments in cancer [1-4]. Unfortunately,
in some tumor’s disease relapse is associated with a multi-drug resistant phenotype that corresponds to
resistance to structurally and functionally divergent agents. Similar to conventional therapies the
success of immune-oncology limited to the occurrence of primary resistance in some patients, as well
as emergence of acquired resistance [5]. Accumulating experimental evidence indicates that the tumor
microenvironment plays a critical role in mediating sensitivity to targeted agents as well as
immunotherapy [6,7]. Thus, to improve the gap in patient outcomes new targets need to be validated in
the context of the metastatic phenotype and the tumor microenvironment. This review will discuss the
potential of ERO1α as target for the treatment of cancer. Despite the endoplasmic reticulum being one
of the largest cellular organelles, it was one of the last ones discovered [8]. Originally described by Emilio
Veratti in 1902, it was not until the electron microscope was available that George Palade and Keith Porter
made the re- discovery [9-11] capturing the structural complexities and tubular structure existing in the
cytoplasm [12]. Since the re-discovery, the ER has been identified to be a continuous membranous
organelle essential for protein folding, calcium storage, lipid metabolism, protein transport, posttranslational modifications, and protein transport via vesicles [13]. It is composed of two main parts:
smooth ER and rough ER. The rough ER is composed of ribosomes and continuous cisternae that
have an important role in protein folding and storage, while the smooth ER is void of ribosomes and
composed mainly of microtubules and is critical for synthesis and storage of lipids. Maintaining
homeostasis within the ER is essential for proper formation of desulphated bridges and ultimately, protein
folding [14]. A major determinant of homeostasis occurs through oxidative enzymes of the flavin
dependent endoplasmic reticulum oxidoreductin-1 (ERO1α) family [15-19] and by the buffering
30

capacity of reduced glutathione (GSH) and oxidized glutathione (GSSG) in a 3:1-6:1 molar ratio in favor
of reduced glutathione [20-22]. ERO1α is known to oxidize protein disulfide isomerase (PDI) to form de
novo disulfide bridges [16]. The crucial function of disulfide bridging occurring in the ER between
ERO1α and PDI have been well-established [23]. Briefly, the target unfolded protein within the ER can
be oxidized by PDI resulting in the reduction of PDI. Oxidized ERO1α can in turn lead to the recycling of
PDI to the oxidized from. Reduced ERO1α can be oxidized and form de- novo disulfide bridge utilizing
FAD as a cofactor leading to FADH and reduction of molecular oxygen to ROS (See Figure 1).
Cancer cells typically are under increased levels of ER stress. ER stress is most evident in secretory
tumors such as multiple myeloma, breast, lung, and pancreatic. However, other inducers of ER stress
include hypoxia and chemotherapy. Given the importance of ER homeostasis, ERO1α-PDI interaction,
and formation of de novo disulfide bridges ERO1α has emerged as a player in the regulation and
tolerance of cancer cells to ER stress [24]. An increase in ER-stress can lead to two possible outcomes:
1.) unfolded protein response (UPR) once activated ultimately brings ER stress back to homeostasis

Figure 1: Upon Phosphorylation of Serine 145 by FAM20C Kinase, ERO1α can return to the endoplasmic reticulum
(ER). Above is an illustration of the interaction occurring between active site of ERO1α, PDI, and Glutathione (GSH).
This reaction is also capable of occurring in the reverse direction resulting in redox equilibrium inside the ER. (Red
circle is the phosphorylation site of ERO1α at serine 145 via FAM20C kinase, Black squares connected by blue
lines are active disulfide bridges required for redox to occur, and black arrows are representative of electron flow
when ERO1α is being reduced.
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via inhibition of translation and inducing cell cycle arrest, or 2.) if ER stress is not resolved than apoptosis
occurs through release of cytochrome C and caspase activation, ultimately protecting the organism from
rogue cells that display misfolded proteins [25]. Despite UPR being the main pathway to ER stress
resolution; UPR has also been linked to autophagic flux. Autophagy can either be inhibited or activated
upon ER stress [26]. Though autophagy is related to ER stress it is not always activated under ER
stress conditions. Autophagy is an orchestrated process by which misfolded proteins, damaged or aged
organelles, or even mutated proteins are sequestered in an autophagosome that ultimately fuses to the
lysosome leading to degradation of sequestered components [27]. Reports recently have showed that
withanolide E in combination with ER stress inducers enhance apoptosis synergistically in pancreatic
cancer models [28]. Multiple cancer types have been reported to have increased ER stress including
multiple myeloma, lung, breast, and pancreatic [29-31]. Differences in ER stress can be driven by
genetic, epigenetic, and microenvironmental heterogeneity that likely result in a range of pro-survival
and anti-apoptotic responses [32]. Anticancer interventions such as chemotherapy has also been
shown to modulate UPR (Unfolded protein response) though clinical implications are only starting to be
understood [33,34]. Recent studies have showed that depending on the context cancer cells can utilize
UPR as a resistance mechanism [35].
Interestingly, overexpression of ERO1α tends to have a worse prognosis in multiple cancer indications;
multiple myeloma [36], breast [37-39] and hepatocellular carcinoma [40], as well as lung, esophageal,
diffuse B-cell lymphoma, and others according to The Cancer Genome Atlas (TCGA) and The Protein
Atlas. These data indicate that expression is increased in aggressive and/or drug resistant disease and
support the premise the ERO1α is a tractable target for the treatment of cancer. Below, we will delve
into four specific topics that will reveal and shed light onto 1.) the structure, function, localization, and
characterization of flavin containing ERO1α, 2.) Disease indications, 3.) immune surveillance, and
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immune evasion and how they are related to ERO1α and 4) chemical probes currently available to test
the ERO1α-PDI pathway.

2.1.3. Structure, Function, Localization, and Characterization of Flavin Containing
ERO1α
Flavoenzymes are an important classification of enzymes that utilize FAD in redox reactions to maintain
enzymatic function. Specifically, ERO1α promotes oxidative protein folding through PDI, producing
hydrogen peroxide as a by-product and is tightly regulated to avoid futile oxidation cycles occurring in the
ER [41]. There are many secretory and membrane proteins under the assistance of thiol- disulfide
oxidoreductases helping form disulfide bonds in the ER [42-46]. The major players in ER oxidative
reactions are ERO1α and PDI; both which are conserved from yeast to mammals [16,17,47,48]. Humans
contain two ERO1 isoforms; ERO1α that is expressed in almost all cell types and ERO1β that is only
expressed in select tissues. The oxidative reaction occurring between ERO1α and PDI produces
hydrogen peroxide, a reactive oxygen species (ROS) [43]. Although a cell can cope with peroxides
formed during basal oxidative protein folding, sometimes using them as secondary messengers in cellsignaling cascades [49] and possibly as a direct protein disulfide introducer [50,51]. If ROS production
exceeds cellular capacity of antioxidants defense systems, this can be harmful via introduction of ER
oxidative stress [41]. ERO1α is tightly regulated not only through phosphorylation state [52], but also
through regulatory disulfide bridging. When disulfide bridges are formed between cysteine 94 and
cysteine 99 ERO1α activity exceeds WT ERO1α (known as hyperactive ERO1α), whereas if cysteine 94
is bridged with cysteine 131 it leads to complete inactivity of ERO1α (Inactive ERO1α) [41]. This was
shown using biochemical approaches through site-directed mutagenesis in yeast. However, this provides
a potential regulatory or even compensatory mechanism that ERO1α can exploit when the ER is under
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extreme stress conditions. Hyperactive, inactive, and WT are the three forms of ERO1α that have been
shown to exist in yeast. In yeast, cysteine 100, cysteine 105, cysteine 352, and cysteine 355 are required
for oxidative reactions, whereas cysteines 90, 208, and 349 are dispensable for these functions [17].
Providing a mechanism by which cysteine 100-cysteine 105 directly engage in oxidative reactions;
whereas cysteine 352-cysteine 355 serve directly to re- oxidize cysteine 100-cysteine 105. Allowing for
ERO1p to undergo another oxidative reaction [16,17,41]. In humans, ERO1α catalyzes the formation of a
cysteine disulfide bond as part of the FAD containing enzyme. As can be seen in Figure 2, the cysteine
397 forms a transition complex with FAD, after which cysteine 94 attacks via a nucleophilic C-S bond to
form the disulfide bond, with FAD reduced to the FADH2. Cysteine 352-Cysteine 355 bridge in yeast are
equivalent to Cysteine 394-Cysteine 397 in humans and undergo the same reaction process with the
cofactor FAD. The regulatory cysteine bridges in yeasts (Cys100-Cys105), is also conserved in humans,
and is the disulfide bridge occurring between cysteine 94-cysteine 99. This disulfide bridge in humans
are responsible for accepting electrons from PDI and transferring them to the disulfide bridge between
cysteine 394-cysteine 397; ultimately allowing for cysteine 397 to perform the nucleophilic attack onto
bound FAD (see Figure 1 and Figure 2). Upon successful oxidative protein folding, basal ERO1α can be
shuttled into the golgi apparatus, where an interaction with FAM20C kinase occurs [52]. FAM20C is a
secretory kinase founded in 2012 known for phosphorylation of the secretory protein Casein.
Interestingly FAM20C prefers to use Manganese (Mn2+) instead of Magnesium (Mg2+) as compared to
other kinases and is known for recognizing S-x-E/pS motif of secretory proteins [53,54]. It has also been
shown to be insensitive to staurosporine, a known broad-spectrum kinase inhibitor. Recently, FAM20C
was shown to phosphorylate ERO1α at serine residue 145 (S145). This phosphorylation state allows for
1 of 2 scenarios to take place; 1.) ERO1α can be sent extracellularly through packaging into exosomes,
or 2.) Is sequestered by ERp44 (an ER transporter and chaperone protein primarily located in the
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endoplasmic reticulum-golgi intermediate compartment (ER-GIC) to be transferred back into the ER to
undergo another oxidation cycle with PDI [55]. Zhang et al. was also able to conclude from their study
that ERO1α activity was increased upon phosphorylation of residue S145, and that this reaction takes
place during mammalian lactation, under hypoxia, and reductive stress conditions. Originally reported to
co-localize with PDI in the ER lumen [16],

Figure 2: A) The structure of ERO1a (3AHQ.pdb) with the FAD binding site shown; B) the orientation of the
Cys394-Cys397 with FAD; C) the proposed catalytic scheme of FAD and disulfide bond formation.

ERO1α has more recently been shown to localize in the golgi apparatus [52], in proximity to the
mitochondrial associated Endoplasmic Reticulum membranes (MAM), but only under oxidizing and
normoxic conditions [56] and was identified from purified exosomes from bladder cancer cells, liver
cancer cells, and squamous cell carcinoma cells (exocarto and protein atlas). More intriguing, ERO1α
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under basal conditions is still found to be localized in the ER despite not having a peptide signal
sequence such as the C-terminus KDEL like other ER-resident proteins [57].
The absence of an ER localization signal suggests that ERO1α functions may extend beyond the ER and
these additional functions based on localization of the enzyme need to be discovered in order to fully
understand role of ERO1α in the progression of cancer. Questions still needing to be answered are 1.)
What function does ERO1α provide by being packaged into exosomes or by remaining in the golgi
apparatus, and 2.) What function does ERO1α have when localized to the MAM region? Though these
questions have not been answered yet fully, there has been some insight onto the function of ERO1α
when localized near the MAM region. This function is to regulate Ca2+ flux. Downregulation of ERO1α
via RNAi was found to inhibit mitochondrial Ca2+ fluxes and modified mitochondrial Ca2+ uniporters.
However, upon overexpression of redox active ERO1α increased passive Ca2+ efflux from the ER was
observed [58]. Calcium flux is an essential ER regulated process that is used in signaling, activation of
apoptosis, and even used in cellular movement. Calcium is stored in the ER but released into the
mitochondria for activation of apoptosis. Calcium can be transferred from the ER into the mitochondria
via the MAM region and is required to maintain cellular homeostasis [59]. Thus, ERO1α functionality
beyond the scope of just protein folding in the ER as localization can play pivotal roles in regulating
protein function.
2.1.4 Disease Indications:
Recently, ERO1α has been reported as a poor prognostic indicator in multiple cancer indications. Yang
et al, showed using genetic shRNA strategies for reducing the expression of Ero1α, in HepG2 and
Hep3B cells that high ERO1α expression correlated with increased migration and invasion. Moreover,
these same investigators showed that in primary patient specimens high ERO1α expression was
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associated with poor clinicopathology of vascular invasion, metastasis, advanced Edmondson grade, and
TNM stage [40]. Yang et al. were also able to conclude from their in vivo studies using HepG2 cells
ectopically expressing ERO1α that an increase in metastatic burden and poor survival in vivo correlated
based with increased ERO1α expression and S1PR1, p-STAT3, and VEGF-A levels. However, upon
depletion of ERO1α using shRNA strategies, S1PR1, p-STAT3, and VEGF-A were also reduced. In
support of clinical data indicating that ERO1α expression is a poor prognostic indicator, we probed the
GEPIA database that utilizes samples from TCGA and GTEX database and compiles the data into a
Kaplan-Meyer plot based on a single gene of interest. Using GEPIA, we determined that that ERO1α is
considered a bad prognostic indicator in multiple cancer indications including Lung Adenocarcinoma,
Hepatocellular Carcinoma, Esophageal Carcinoma, and Diffuse B-Cell Lymphoma (see Figure 3 and
Table 1). Moreover, genetic and pharmacological studies in cell lines has indicated that ERO1α
expression and function contributes to an aggressive cancer phenotype (see Table 1).The GEPIA was
able to confirm that high ERO1α transcript levels correlate with worse prognosis in multiple cancer
indications. As mentioned previously ERO1α is responsible for protein folding. More specifically, ERO1α
is directly involved in folding of membrane and secretory proteins [64]. Recently, ERO1α has also been
shown to have a role in post-translational modification of β1 integrin in colorectal cancer cell when under
hypoxic conditions. When ERO1α is knocked out using CRISPR Cas9 in HCT116 colorectal cancer cells
and placed under hypoxic conditions it was found that the glycosylation state of integrin β1 was changed
and thus an attenuation of integrin β1 on the cell membrane occurred; ultimately leading to contactinhibited morphology [57]. These are just a few examples of many that ERO1α is associated with cancer
indications
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Figure 3: Top Left Panel represents survival data for Lung Adenocarcinoma in respect to ERO1α, Top Right Panel
represents Esophageal Carcinoma, Bottom Left Panel represents survival data for hepatocellular carcinoma, and
Bottom Right Panel represents survival data for diffuse B-cell lymphoma. Kaplan-Meyer Plots above were plotted
using ERO1α gene filter in GEPIA, which obtains data from TCGA and GTEx databases.
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Table 1: Role of ERO1α in cancer progression and metastatic potential in cancer.

Cancer
Type

Breast

Hepatocellular Carcinoma

Head and
Neck

Cell
Type

Native ERO1α
expression

Tools used

Native expression
effect/silencing effect

Reference’(s)

9A3, 9C1,
9C2,

Comparable to
MDA-MB-231

↑ERO1α
↓ERO1α/shRNA

↑ PD-L1; dependent on
oxidative folding

[60]

MDAMB-231,
9A3, 9C1,
9C2

Comparable to
MDA-MB-231

↑ERO1α
↓ ERO1α/shRNA

↑ angiogenic potential via
VEGF secretion, ↑ tumor
growth

[39]

[61]

[37]

MCF10A

Comparable to
MCF-7

-

Tumor associated
Macrophages increased
ERO1α expression,
causing ↑MMP-9
expression, and ↑
invasion

4T1

Comparable to
healthy mouse
mammary tissue

↑ ERO1α
↓ ERO1α/shRNA

↓ ERO1α expression
lead to ↓ tumor burden:
↑ ERO1α ↑ MDSC’s and
leads to immune evasion

4T1
Triple
negative
patient
samples

Comparable to
healthy mouse
mammary tissue;
Healthy human
breast tissue

MDAMB-231

Comparable to
MDA-MB-468

Patient
samples,
LO2, Huh-7,
HEP3B,
SMMC7721,
HEPG2,
MHCC-97H

ERO1α
expression lower
in healthy tissue
compared to
tumor samples
and cell lines

HN4, CAL27

-

↓ tumor burden, ↓ lung
metastasis;
↓ ERO1α/shRNA

Patients with ↑ ERO1α
expression had worse
prognosis overall.
MTH-3 treatment lead to
↓ ERO1α, activation of
autophagy, and lead to
apoptosis

-

↓ ERO1α/shRNA
↑ ERO1α
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[62]

↓ ERO1α lead to less
metastasis and decreased
tumor burden.
[40]
↑ ERO1α lead to increase
metastatic potential and
increased tumor burden.
Tunicamycin treatment
↑ER stress, ↑ ERO1α
expression, and ↓overall
tumor burden

-

[38]

[63]

Multiple
Myeloma

Patient
samples
U266,
MM1.S

Increased
ERO1α
expression poor
prognostic
indicator
in multiple
myeloma

Chemical
EN-460
PB-EN-10

Pharmacological
inhibition Ero1α lead
apoptosis and ER stress
in U266 myeloma cell
line

[36]

(-) indicates no available data

2.1.5. Immune Surveillance and Immune Evasion Correlate with ERO1α Expression

Recently, immuno-oncology (IO) has demonstrated to be a tractable strategy for achieving durable
responses. Targets and delivery approaches which may enhance IO response with respect to
percentage of patients that respond remains an active area of research (rev in [65]). As IO approaches
move toward combination strategies, it is essential to determine the effect of modulating novel targets such
as Ero1α on the immune tumor microenvironment. Immunotherapies have previously failed in lung cancer
but has recently emerged as very effective new therapy [66], with the emergence of immune checkpoint
blockade such as anti-PD-1 (programmed cell death-1) antibodies and anti PD-L1 (programmed cell
death-ligand 1) antibodies [67]. ERO1α is thought to be responsible for the processing and folding of PDL1 and PD-1. PD-L1 is a transmembrane protein located on the cell surface of placental, vascular
endothelium, pancreatic islet, muscle, and mesenchymal stem cells [68], and PD-1 is a receptor
belonging to the CD28 family of receptors that is only expressed on the surface of activated T-cells, Bcells, and myeloid cells [69]. The binding of PD-L1 to PD-1 is an immune suppressive signal that inhibits
autoimmunity through induction of T-cell apoptosis [70] and induces tolerance [71]. Recently, a study has
shown that ERO1α promotes immune escape through up-regulation of PD-L1 in breast cancer [60]. This
connection is due to the intramolecular disulfide bond that exist in PD-L1 [72] and ERO1α is a known
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contributor to folding of membrane proteins as well as introduction of disulfide bonds [16]. In this recent
finding, Tanaka et al. [60], was able to demonstrate that ERO1α up-regulates PD-L1 surface expression
not only through oxidative folding, but also unexpectedly up-regulated PD- L1 mRNA expression through
augmentation of hypoxia inducible factor-1alpha (HIF-1α) in human triple negative breast cancer cell
lines. Although this occurrence could be diminished upon knockdown of ERO1α using RNA Interference
(RNAi), as it led to significant attenuation of PD-L1 mediated T-cell apoptosis [60]. This provides insight
towards hypoxia mediated immune resistance; specifically, in triple negative breast cancer cell lines. As
shown previously in Figure 2, increased expression of ERO1α is a poor prognostic indicator in lung
adenocarcinoma, hepatocellular carcinoma, esophageal carcinoma, and diffuse B-cell lymphoma;
However, ERO1α has also be found to be a poor prognostic indicator in breast cancer by multiple
researchers [37,38].
Alongside the discovery of PD-L1 and PD-1, of which Dr. Allison and Dr. Honjo won the 2018 Nobel
Prize for the discovery of checkpoint blockades PD-1, PD-L1, and CTLA-4, the discovery of myeloid
derived suppressor cells (MDSC’s) has also had an outstanding impact clinically. Reports of MDSC’s
associated with tumor progression go back to the 1970’s [73]. However, during the 1980’s and early
1990’s, laboratories of Diana Lopez, Jim Talmadge, M. Rita Young, and Hans Schreiber, demonstrated
various types of myeloid cells could inhibit immune functions in cancer [74]. There are two main groups
of MDSC’s; Polymorphonuclear MDSC’s (PMN-MDSC’s), and monocytic MDSC’s (M-MDSC’s). In recent
years it has become clear that these two groups function differently in terms of immune suppression
during tumorigenesis. M-MDSC’s suppress the immune system in both antigen- specific and non-specific
manners utilizing mechanisms associated with production of NO and cytokines [75]. PMN- MDSC’s on the
other hand can suppress immune responses primarily in an antigen-specific manner, inducing antigen
specific T-cell tolerance is a major characteristic of these cells [76,77]. Recently it has been shown that
41

tumor cells are a source of granulocytic colony stimulating factor (G-CSF) [78-81], and that production of
G-CSF by tumors are responsible for recruitment of immunosuppressive PMN-MDSC’s, which promote
tumor growth via inhibition of antitumor immune responses [82,83]. G-CSF is a glycoprotein that functions
as a hematopoietic cytokine that is secreted from immune, endothelial and bone marrow stroma cells
leading to production of granulocytes (granulopoiesis), as well as contributes to mobilization of stem cells
[84]. Amongst G-CSF’s many functions, it is a secretory protein that’s folding cycle is predicted to occur
through ERO1α. In a recent publication; Tanaka et al. [37] demonstrated that ERO1α plays a pivotal role
in PMN- MDSC induction via up-regulation of G-CSF production from cancer cells in collaboration with
PDI. Tanaka et al. [37] were also able to demonstrate that reduced expression of ERO1α through shRNA
strategies reduced tumor growth by restoration of antitumor T-cell-mediated immunity, and ERO1α
overexpression promoted tumor growth in vivo via suppression of antitumor immunity.
Immune system functionality has been well defined for quite some time. Despite immune system
functionality being well described, cancer researchers are still discovering resistance mechanisms to
cancer therapies that are utilizing the host immune system. Recently, it was found that hypoxia
augmented the endogenous major histocompatibility complex I (MHC Class I) presentation in murine
tumor cells [85]. MHC Class I molecules are responsible for presentation of endogenous antigens,
expressed on all nucleated cells, and present protein fragment of cytosolic or nucleic nature to CD8+
T-cells on the cell membrane. [86]. These antigens are peptide fragments that are intracellular and
obtained from multiple pathways being approximately 8-10 amino acids long [87]. MHC Class I molecules
are stabilized by ER chaperones such as ERp57, PDI, and tapasin [86]. Upon binding of the designated
peptide antigen to the MHC Class I molecule, the chaperones are released and fully assembled,
peptide- MHC Class I complexes leave the ER for presentation of the cell membrane [87]. Conversely, the
MHC-Class I peptide complexes that fail to associate in the ER are sent to the cytosol to undergo
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proteasomal mediated degradation [88,89]. Though the function of MHC Class 1 is clear, it is not clear if
this function is augmented in tumors or during hypoxic conditions. HIF-1α is known to be induced under
hypoxic conditions and more recently has been shown to regulate expression of ERO1α [90,91]. More
specifically, ERO1α was induced in hypoxic conditions in a HIF-1α dependent manner [91]. May et al.
[91] were also able to demonstrate that ERO1α was not induced under hypoxic conditions in fibroblast
cell lines derived from HIF-1α knockout mice, revealing ERO1α as a transcriptional target of HIF-1α. To
induce an effective antitumor immunity using cancer antigen peptide-based immunotherapy, a
cancer antigen must be appropriately presented on MHC Class I molecules [37]. Kukita et al. [37]
were able to determine three distinct effects that hypoxia had on MHC Class 1 presentation; 1.)
Expression of MHC Class I peptide complex on the cell surface was augmented, 2.) Activation of
antigen specific CD8+ T-cells was augmented, and 3.) Specific cytotoxic T-lymphocytes were capable of
killing tumor cells under hypoxic conditions. They were also able to determine that ERO1α was
responsible for the hypoxia driven antigen presentation by MHC Class I molecules. ERO1α is
responsible for the disulfide bond formation of MHC Class I heavy chains. Upon depletion of ERO1α,
MHC Class I expression on the cell surface was also shown to be decreased, resulting in decreased
cytotoxic T-lymphocyte reactivity [37]. Thus, Kukita et al [37] were able to demonstrate that ERO1α
plays a crucial role in hypoxia-induced oxidative folding of MHC Class I heavy chain, leading to
augmentation of MHC Class I-peptide complex on the tumor cell surface and enhanced recognition by
antigen specific cytotoxic T-lymphocytes. Functional MHC Class I expression is needed to induce cell
death via induction of CD8+, T-lymphocytes. Despite increased MHC Class I expression in hypoxic
conditions, the increased and chronic presence of cancer associated antigens may lead to T-cell
exhaustion in hypoxic regions of the tumor, albeit further work is required to fully determine whether
increased Ero1α expression leads to T-cell exhaustion in vivo [92, 93]. Because inhibiting Ero1α is
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likely to change the cytokine and chemokine profile of the tumor
microenvironment, further studies are required to fully understand
the effect of inhibiting ERO1α on tumor mediated immune
suppression.
2.1.6. Inhibitors of the ERO1 Pathway
Currently pharmacologic inhibitors that target ERO1α are limited.
The first inhibitor of ERO1α, known as EN460, and was identified
through a screen of 210,960 natural compounds [94]. EN460 is
specific for the reduced active form of ERO1α and prevents reoxidation [94]. Our laboratory recently demonstrated that EN460
could potentially be used to treat cancers with high ER-stress
such as multiple myeloma [36]. It was also confirmed during this
study that EN460 had multiple off targets; all being
flavoenzymes, or enzymes that contain flavin adenine
dinucleotide (FAD). Our laboratory was also able to develop an azide derivative of EN-460, PB-EN-10,
that showed similar effects [36]. The tool compound EN460 and its azide derivative PB-EN-10 are shown
below in Figure 4. Having direct interactions with PDI during oxidative protein folding it seems feasible
that PDI could also be targeted to inhibited ERO1α mediated biological functions. PDI has also been
shown to be a potential target in multiple myeloma. Targeting PDI provides its’ own challenges as it has
multiple isoforms being a family with greater than 20 members, and due to the multiple redox active
cysteine residues present [95-98]. PDI inhibition currently via small molecules occurs through covalent
catalysis and includes the following tool set 16F16, PACMA31, KSC- 34, E61, and E64FC26 [99-102].
Despite multiple known inhibitors against PDI, none have entered clinical trials for the treatment of cancer
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at this time. ERO1α and PDI could be good targets in cancer indications if specificity could be achieved
toward both enzymes, as PDI inhibitors tend to hit all PDI family members and ERO1α inhibitors have the
tendency to target other flavoenzymes. In conclusion ERO1α is emerging as an attractive target for the
treatment of cancer. Supporting evidence that credentials the target described above includes i) clinical
data indicating that increased expression of the enzyme is a poor prognostic indicator in multiple cancer
indications and ii) genetic strategies utilizing shRNA indicate that reducing the expression of ERO1Lα
inhibits growth and metastasis using both in vitro and in vivo model systems. However, delineation of the
therapeutic window will require a drug discovery campaign to elucidate more specific and potent
inhibitors to allow for further validation of the target.
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3.1.1 Abstract:
The flavin adenine dinucleotide containing Endoplasmic Reticulum Oxidoreductase-1 α (ERO1α)
catalyzes the formation of de novo disulfide bond formation of secretory and transmembrane proteins and
contributes towards proper protein folding. Recently, increased ERO1α expression has been shown to
contribute to increased tumor growth and metastasis in multiple cancer types. In this report we sought to
define novel chemical space for targeting ERO1α function. Using the previously reported ERO1α inhibitor
compound, EN-460, as a benchmark pharmacological tool we were able to identify a sulfuretin derivative,
T151742 which was approximately two-fold more potent using a recombinant enzyme assay system (IC50
= 8.27 ± 2.33 µM) compared to EN-460 (IC50= 16.46 ± 3.47 µM). Additionally, T151742 (IC50 = 16.04 µM)
was slightly more sensitive than EN-460 (IC50= 19.35µM) using an MTT assay as an endpoint. Utilizing a
cellular thermal shift assay (CETSA), we determined that the sulfuretin derivative T151742 demonstrated
isozyme specificity for ERO1α as compared to ERO1β and showed no detectable binding to the FAD
containing enzyme LSD-1. T151742 retained activity in PC-9 cells in a clonogenicity assay while EN-460
was devoid of activity. Furthermore, the activity of T151742 inhibition of clonogenicity was dependent on
ERO1α expression as CRISPR edited PC-9 cells were resistant to treatment with T151742. In summary
we identified a new scaffold that shows specificity for ERO1α compared to the closely related paralog
ERO1β or the FAD containing enzyme LSD-1 that can be used as a tool compound for inhibition of
ERO1α to allow for pharmacological validation of the role of ERO1α in cancer.

Key words: redox; PDI, FAD, flavoenzyme, ERO1α, lung cancer
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3.1.2 Introduction:
Lung cancer remains the most common cancer death worldwide at approximately 1.6 million deaths
occurring each year. Non-small lung cancer treatment regimens have had increasing clinical benefit over
the last two decades with the discovery of molecular drivers and development of tyrosine kinase inhibitors
and immunotherapies1. However, emergence of resistance to targeted and immunotherapies remains a
clinical obstacle for increasing overall survival and improving patient outcomes2-5. Recently, increased
expression of endoplasmic reticulum oxidoreductin-1 alpha (ERO1α) has been identified as a key player
in promoting metastatic burden, proliferation, immune escape, and increased expression of ERO1α
correlates with worse clinical outcomes in multiple tumor indications6-11. ERO1α belongs to the
flavoenzyme family of enzymes. Flavoenzymes are enzymes that meet two criteria; 1.) the enzyme must
be an oxidoreductase and 2.) must contain flavin adenine dinucleotide (FAD) as a prosthetic group 12.
Examples of flavoenzymes include ERO1α, ERO1β, LSD-1, MAO-A, and MAO-B. The endoplasmic
reticulum (ER) resident enzyme ERO1α is known to form de novo disulfide bridges and aid in folding of
transmembrane and secretory proteins in conjunction with protein disulfide isomerase (PDI)
molecular interactions and oxidation of PDI and protein folding has been well established

13-16.

17, 18.

ERO1α

While in

its’ reduced form ERO1α utilizes molecular oxygen, becoming oxidized, while reducing FAD through
electron transfer and producing hydrogen peroxide as an intermediate. This process is important for the
formation of disulfide bond formation that occurs during the protein folding process. Despite the cell being
able to deal with minimal peroxide intermediates, it is also tightly regulated to avoid futile oxidative cycles
from occurring in the ER, and therefore, aids in maintaining homeostasis within the ER

19.

ERO1α and

PDI are the two main players in oxidative reactions occurring within the ER, both which are highly
conserved from yeast to mammals 13-16. Upon homeostatic imbalances within the endoplasmic reticulum,
the unfolded protein response is generally activated; resulting in one of two possible outcomes: 1.) the
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unfolded protein response can return endoplasmic stress to homeostatic levels, or 2.) if homeostasis
can’t be established then apoptosis can be activated 20, 21. Thus, the unfolded protein response is a
cellular response mechanism for resolving ER stress which can lead to survival or death depending on
the context. Due to the critical enzymatic function, it is not surprising that ERO1α is tightly regulated via
post-translational phosphorylation22, and through regulatory disulfide bridging. Cysteine bridging between
Cys94-Cys99 allows for nucleophilic attack on bridged cysteines of Cys394-Cys397, allowing for Cys397
to undergo a nucleophilic attack onto bound FAD23. This reaction process utilizes molecular oxygen as a
terminal electron acceptor to form hydrogen peroxide as an intermediate. Cancer cells typically have
increased ER stress compared to normal cells and occurs more so in secretory tumors such as lung,
breast, multiple myeloma, and pancreatic cancers, but other tumors can exhibit high levels of ER stress
following exposure to chemotherapy or hypoxia24-27. ERO1α plays a crucial role in ER homeostasis, via
its’ interaction with PDI to aid in protein folding, and has emerged as a key player in aiding in tolerance of
cancer cells to ER stress28. Despite the emerging evidence that ERO1α is an attractive target, few
chemical probes are available to allow for further validation of the target. The challenge in part is due to
the conserved nature of the FAD binding domain across enzymes. Developing specific inhibitors or more
potent inhibitors to a specific flavoenzyme is critical for pharmacological validation of the target. Despite
this challenge there are flavoenzyme targeting agents that are more specific such as the LSD-1 inhibitor
IV. LSD-1 inhibitor IV forms a covalent adduct with FAD within LSD-1 and is approximately 6-fold more
selective toward LSD-1 compared to MAO-A and MAO-B, and was originally described and synthesized
by Neelamegam et al29. The first reported ERO1α inhibitor was identified from a high-throughput screen.
The hit molecule called EN-460 was shown to inhibit ERO1α activation and prevent re-oxidation30.
However, recently our laboratory demonstrated that EN-460 inhibits multiple flavoenzyme family
members including LSD-1, MAO-A, and MAO-B6 and thus EN-460 is not an ideal compound for
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pharmacological credentialing of ERO1α. Due to this gap in knowledge, we sought to identify additional
chemical space for targeting ERO1α.
The aurone class of compounds with sulfuretin as primary example, is a major group of flavonoid
small molecules isolated from the heartwood of Rhus verniciflua and can be used to reduce oxidative
stress31. Chalones are another class of flavonoids that exhibits a close biochemical relationship with the
aurones32. Flavonoid compounds belong to the low-molecular-weight class of phenolic compounds that
are widely distributed in the plant kingdom33. Flavonoid compounds contain specific structural features
being the 2-phenyl-benzol (α)pyrane, containing two benzene rings, linked by the heterocyclic pyrane
ring34. The main classes of flavonoids includes the aurones, chalcones, flavones, flavonones, flavonones,
isoflavones, antrocyanidins, flavan-3-ols, flavans, flavan-3,4-diols, dihydrochalcones, and
proanthocyanidins35, 36. Flavones are classified by the double bond at position 2 and 3 with a ketone at
position 4 of the C ring while, most flavones have a hydroxyl group occurring at position 5 of the A ring 33.
In this paper we sought to determine whether the aurone and/or chalcone family demonstrates activity
toward ERO1α and to determine the specificity of the most potent analog.
3.1.3 Results and Discussions:
Determination of inhibition of ERO1α by sulfuretin derivatives
Based on previous work which established an aurone chemical class of compounds as FAD containing
enzyme inhibitors37, we evaluated sulfuretin analogs for ERO1α enzyme inhibition. The Amplex Red
assay was used to determine if the sulfuretin derivatives were capable of inhibition of ERO1α in a
recombinant assay system previously established by our laboratory6. As shown in Figure 1, the sulfuretin
derivatives inhibited ERO1α in a concentration dependent manner. The most potent aurone analog
referred to as T151742 was found to be approximately 2-fold more potent compared to EN-460 (IC50 =
8.27 ± 2.33 µM), T151750 (IC50 = 11.34 ± 2.49 µM), T151688 (IC50 = 18.91 ±5.47µM) and EN-460 (IC50
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=16.46 ± 3.47µM). Based on our initial studies shown in Figure 1, we sought to determine whether the 4dimethylamino on the benzylidene ring was critical for inhibition of ERO1α and synthesized a small set of
compounds to determine the impact of substitution on the benzylidene ring has on enzyme activity. The
compound structures are shown in Figure 2 and Table 1 and were tested at 10 µM which is the
approximate IC50 of T151742. The sulfuretin derivatives were found to inhibit ERO1α, with the Aurone
scaffolds demonstrating similar activity to the chalcone compounds (Table 1). With the small changes in
activity profile, our findings suggest that the 4-dimethylamino-moiety to be important for activity, since
none of the new aurones or chalcones were more potent than T151742. Additionally, the para-hydroxy on
the benzofuran is important for activity, as loss of this functional group led to a decrease in inhibition
activity. Comparing the electrostatic surfaces of EN-460, to the compounds tested here, we found that
interestingly, T151742 shared a similar surface pattern as EN-460, while other compounds such as SR-F126, SR-F-128, and T151750 shared some overlap in electrostatics, but were less pronounced and
concentrated in certain areas, as compared to EN-460 (Figure 3). This in part could explain the
differences in activity profile of the compounds compared to T151742, and EN-460. Since the newly
identified sulfuretin derivative T151742 was the most potent of the compounds tested we evaluated its
activity profile in classical enzyme kinetics assays. Currently, the standard model of FAD-containing
enzymes, is that the inhibitors available inhibit flavoenzymes interaction directly with FAD substrate
pocket and are competitive inhibitors, with a select set of compounds designed as covalent inhibitors 38.
To validate the mechanism of inhibition T151742 had on ERO1α, varying PDI concentrations (the
substrate for ERO1α), and varying concentrations of T151742 were used and the double reciprocal of this
plot was taken to produce the Lineweaver-Burk plot (See Figure 4A and 4B). As shown in Figure 4A
and 4B, KM is increased while VMax is reduced with the increasing concentration of T151742. This is
observed in the double-reciprocal plot in Figure 4B, as slope of the lines increase in a concentration
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dependent manner, and both x and y-intercepts change in a concentration dependent manner as well.
These findings suggest that T151742 was acting upon ERO1α as a non-competitive (mixed) inhibitor and
was not binding directly to the active site.
Surface plasma resonance (SPR) was utilized as an orthogonal assay to confirm direct binding between
T151742 and ERO1α. For the SPR assay, recombinant ERO1α was crosslinked to a C5 chip and
varying concentrations of ligand T151742 were evaluated for detection of changes in refractive index, due
to change in mass on the chip when ligand is bound to the protein. As shown in Figure 4C, T15742 binds
to ERO1α in a concentration dependent manner with a Kd =31.4 µM. The relatively high Kd value is in
part due to the fast off-rate. Taken together, our data indicate that the sulfuretin derivative T151742 i)
binds directly to ERO1α in a recombinant system ii) is the most potent analog in this small series at
inhibiting ERO1α, and two-fold more potent than EN-460, iii) acts as a non-competitive (mixed) inhibitor
and iv) a remaining potential liability is the fast off rate of the compound. Several of the flavoenzyme
family of proteins contain a substrate pocket in which specific substrates are metabolized in the presence
of FAD, e.g., dopamine with MAO-A39. This has led to the development of irreversible covalent inhibitors
of the cofactor FAD such as tranylcypromine40. The development of the covalent inhibition led to the
inclusion of the active moiety propargylamine, leading to derivatives deprenyl/selegiline and rasagiline
which are used clinically to treat Parkinson’s disease41. Furthermore, the LSD-1 inhibitor IV, RN-1 was
amongst the first lysine demethylase inhibitors discovered, where LSD-1 is a FAD containing enzyme29.
Tranylcypromine forms a covalent modification directly with FAD40. LSD-1 inhibitor IV, RN-1 contains the
classical tranylcypromine-template that allows for covalent modification of targeted enzymes containing a
FAD moiety. We determined that the LSD1 inhibitor IV and tranylcypromine both known to covalently
crosslink FAD did not inhibit ERO1α activity (See Supplemental Figure 1 for concentration response).
Conversely, T151742 was shown not to inhibit LSD-1 enzymatic activity (See Supplemental Figure 2 for
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concentration response) These data suggest that the FAD containing ring within ERO1α is concealed
within the enzyme and not easily targeted by small molecules. Based on the crystal structure of ERO1α,
(3ahq.pdb), the FAD is contained in a pocket close to the redox active cysteines, fully occupying the
pocket space. Taken together, these findings suggest that the putative binding pocket of the ERO1α
inhibitors are not in the FAD pocket but is likely allosteric to the FAD binding pocket. Based on the
experimental data we explored binding pockets allosteric to the FAD binding pocket of ERO1α. The Site
Finder algorithm of MOE 2020 was used to identify the putative pocket in proximity to the FAD binding
pocket, as well as the reactive cysteines CYS394 and CYS397 (Figure 5A). We used the reduced form
of the crystal, based on our enzyme assay which still produced hydrogen peroxide in presence of the
inhibitors. As shown in Figure 5A T151742 was predicted to bind by hydrogen bonding to GLN93 and
GLY138 with the 3-ketone oriented towards the reactive cysteines CYS394 and CYS397 (<4 A). Figure
5B shows that loss of the 6-hydroxyl moiety which yielded T151688 lead to a loss of the GLN93 binding
interaction, potentially contributing to differences in activity when comparing T151742 with T151688.
Predicted affinity using YASARA Autodock Vina corroborated these findings, with a predicted inhibition of
2.31µM for T151742 and 13.67µM for T151688. Lastly, Figure 5C shows that loss of the 4dimethylamino in T151750 leads to loss of the 3-ketone hydrogen bond with GLY138 as compared to
T151742. From these docking studies, we propose that the ERO1α inhibitors are interacting with ERO1α
via an allosteric binding site located in proximity to the redox active CYS394-CYS397 pair, preventing the
oxidation of the disulfide bond.
Determining the selectivity of T151742 using in vitro cell culture models
The ERO1α inhibitor EN-460 found in a high-throughput screen from natural products was shown to
inhibit the reduced form of ERO1α30. However, this compound has a liability as a tool to
pharmacologically validate ERO1α as a target as it has been shown to inhibit other flavoenzyme family
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members including; LSD-1 MAO-A, and MAO-B6, 30. It was previously shown that T151742 showed
activity against MAO-A and MAO-B, albeit was not the most potent Aurone member37. To date activity of
T151742 towards other flavoenzymes has not been identified at this time. We utilized the Cellular
Thermal Shift Assay (CETSA) to determine target engagement of T151742 in vitro using the non-small
cell lung cancer (NSCLC) cell line PC-9. The EGFR driven PC-9 cell line was chosen as new treatment
strategies are needed in EGFR driven NSCLC as most patients relapse and become resistant to current
targeted therapies with development of further mutations such as T790M, C797S as well as emergence
of EGFR independent tumors42, 43. CETSA utilizes thermodynamic principles that have been well
described and upon binding of ligands to a protein, the ligand bound protein becomes more thermostable with respect to the temperature required to denature the protein or expose hydrophobic regions of
the protein leading to aggregation and insolubility of the protein44. All proteins have an aggregation
temperature which is inherent to their intracellular thermostability. Upon addition of a ligand binding, the
thermostability increases. First, we determined the aggregation temperature (Tagg) of ERO1α, ERO1β,
and LSD-1, which are all FAD dependent enzymes and potential in vitro targets of T15742. Tagg was
defined as the point at which 10% of protein or less is remaining when compared to the room
temperature control of the target protein by western blot analysis. As shown in Figure 6A, CETSA
analysis determined that the Tagg for unbound target protein (ERO1α Tagg = 54˚C; ERO1β; Tagg =
54˚C; and LSD-1 Tagg = 52˚C). The values reported are averages from three independent experiments.
When T151742 was added to the culture media at a concentration of 100µM for 1 hour at 37˚C the Tagg
for ERO1α shifted approximately ~6 degrees to >60˚C (See Figure 6A). In contrast, incubation of cells
with 100µM T151742 did not change the Tagg for LSD-1 or ERO1β. These results indicate that T151742
bound and stabilized ERO1α compared to the flavoenzymes ERO1β and LSD1. Although ERO1α and
ERO1β, have highly conserved sequences and functions it appears their tertiary structures are more
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diverse than previously thought and specific inhibitors can be developed to distinguish the activity of
inhibiting one enzyme using in vitro models. The Tagg for LSD-1 also remained unchanged upon addition
of T151742 and aided in confirming that T151742 shows more specificity towards ERO1α as compared to
other members of the flavoenzyme family, with the exception of MAO-A which was previously reported37.
The results of the CETSA assay combined with the in vitro recombinant assay demonstrated that
T151742 does not inhibit enzymatic activity of LSD-1 (See Supplemental Figure 2 for concentration
response).
Evaluating the efficacy of T151742 in the PC-9 lung cancer cell line
We utilized an MTT assay to determine the potency of the compounds for inhibiting cell growth. As
shown in Figure 6B; we compared T151742, EN-460, and SR-F-114. Consistent with the enzymatic
assay T151742 was most the most potent while SR-F-114 was approximately two-fold less active.
(T151742 IC50 = 14.05

3.99 µM, EN-460 IC50= 16.62

4.34 µM, and SR-F-114 IC50= 32.36

6.01).

We next asked whether T151742 induced inhibition of cell growth was dependent on ERO1α expression.
As shown in Figure 6C two ERO1α deleted clones in the PC-9 cell line were isolated. Using an MTT
assay to determine overall cellar viability, a non-targeted control (scramble), and both ERO1α knockout
clones was subjected to treatment with T151742 for 72 hours (See Figure 6D). PC-9 ERO1α deleted
cells were approximately 2-3 fold more resistant to T157742 treatment compared to the control cell line
(PC-9 WT IC50 = 14.13µM ± 1.15, PC-9 ERO1α KO Clone 1 IC50 = 32.23 ± 1.09µM and PC-9 ERO1α KO
Clone 2 IC50 = 41.54 ± 1.08µM. We were also able to determine that the IC50 values in myeloma cells
lines was 7-9 M indicating that myeloma cells demonstrate increased sensitivity to inhibition of ERO1α.
These data suggest ERO1α maybe important to further credential as a target for the treatment of multiple
myeloma. Importantly, the normal lung epithelial cell line Beas-2B the IC50 value was found to be
>100µM suggesting that cancer cells are more dependent on ERO1α compared to normal cells (See
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Supplemental Table 1 for IC50 values of all cell lines tested). Though only slight differences were
observed between T151742 and EN-460 we tested the effects of these compounds in a clonogenic assay
which is a better test for inhibition of self-renewal. Utilizing soft agar assays we were able to determine
that T151742 was significantly more potent at reducing colony number in a concentration-dependent
manner in comparison to EN-460 (Figure 7A-B). PC-9 ERO1α knockout clones were found to be
completely resistant to T151742 using a clonogenic assay as an endpoint (Figure 7C-D). Together, these
data suggest that the activity of T151742 is dependent upon ERO1α expression when using clonogenicity
as an endpoint.
3.1.4 Conclusions:
In conclusion, we identified T151742 as the most potent aurone analog which demonstrated activity
against ERO1α. With T151742 having activity against ERO1α in a recombinant assay system and binds
the target using in vitro assays. Aurone and chalcone molecules synthesized showed similar activity, but
no derivatives made were found to be more potent than T151742. We were also able to demonstrate
that T151742 activity was completely dependent on ERO1α expression using soft agar clonogenic assay
as an endpoint. Additionally, our data indicate that clonogenic assays may be a better endpoint compared
to proliferation or a death assay when screening compounds against ERO1α. The CETSA assay
indicates T151742 has specificity towards ERO1α over other flavoenzymes, and these data indicates this
assay can be used to validate ERO1α target coverage using in vitro. Further studies are required to
determine whether the CETSA assay can be used to determine target coverage of ERO1α using in vivo
models of cancer. Lastly, we were able to determine through structure-activity relationship built upon here
that both the hydroxyl group at position 5 on the A ring and the tertiary amine group on the B ring are
important for activity against ERO1α, as all derivatives with changes at these positions lost efficacy
towards ERO1α in our recombinant system. Ultimately, our results suggest the aurone scaffold can be
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exploited to further develop novel specific inhibitors to pharmacologically credential the target ERO1α
using in vitro models of cancer. Future studies are warranted to determine whether T151742 can be
used to credential ERO1α using in vivo models of cancer. Studies using a clonogenic assay comparing
EN-460 and T151742 suggest that specificity maybe more important for targeting self-renewal or
clonogenic growth in soft-agar. However, further studies will be required to determine whether a
promiscuous inhibitor targeting multiple FAD containing enzymes will be more effective compared to
specific targeting of ERO1α for the treatment of cancer.
Supporting Information Available: This material is available free of charge online. Additional
experimental details and methods for the synthesis are included, as well as the 1H and 13C NMDR
spectra and HPLC chromatograms. Additional experimental data presented demonstrates that covalent
modifiers of FAD do not inhibit ERO1α enzymatic activity and T157142 does not inhibit LSD-1 enzymatic
activity.
3.1.5 Materials and Methods:
Compounds used in the assays were obtained from commercial sources. EN-460 (Sigma Aldrich, CAT#
328501), LSD-1 Inhibitor IV (Sigma Aldrich, CAT# 489479), and Tranylcypromine (Sigma Aldrich, CAT #
616431) were purchased. All T151742 derivatives that were used in experiments were made synthetically
and experimental procedures on synthetic strategy, 1H, 13C, 13C-DEPT & 19F NMR Spectra with HPLC
traces of compounds, high-resolution mass spectrometry (ESI-TOF), yield, melting points, and purity of
compounds tested are attached in Supplemental information.
Protein Expression, Purification, and Enzymatic assays: Human ERO1α (a.a. 22-468) containing
hyperactivating triple mutation (C104A, C131A, and C166A

19)

was purified as previously described 6.

Human PDI (a.a. 18-479) was synthesized and purified as previously described6. Quantification of
enzymatic activity of ERO1α was performed using the amplex red as previously described6.
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Cell Lines: PC-9 cell line used was obtained from Sigma Aldrich and grown in RPMI 1640 medium with
10% fetal bovine serum and 1% penicillin/streptomycin. HCC4006, U266, MM1.s, and Beas-2B cell lines
were obtained from ATCC and cultured in either RPMI 1640 or DMEM with 10% fetal bovine serum and
1% penicillin/streptomycin. All cell lines were also checked for mycoplasma every six months and
subjected to short tandem repeat (STR) analysis for cell line validation.
CRISPR Cas9: CRISPR Guide RNA 2 (TGTGAACAAGCTGAACGACT) targeting ERO1α and CRISPR
Guide RNA 4 (AATTAAATCTGCGAGCTACA) were purchased from Genscript in the pLentiCRISPR V2
plasmid containing puromycin/ampicillin selection marker. Lentivirus was made from HEK 293T cells by
co-transfection with GuideRNA of interest, pVSVG, and pPAX2 plasmids. Lentivirus was collected after
48 hours and concentrated using 40% PEG8000. Concentrated virus was used to infect PC-9 cells. Cells
were placed under puromycin selection after 72 hours and cloned out using limiting dilutions.
Lineweaver-Burke: Varying concentration of PDI (0mg/mL - 0.25mg/mL) and T151742 were assayed
using the Amplex red kit as described above. The reaction was incubated for 30min at 37˚C for 30
minutes. Plate was then read on the Biotek Cytation 5 at 530/590nm.
MTT: Cells were plated at 10,000cells/well in quadruplets in a 96 well plate and allowed to attach for 24
hours. EN-460 or T151742 were added at increasing concentrations (100µM, 50µM, 25µM, 12.5µM,
6.25µM, 3.125µM. 1.5625µM) with DMSO as control and allowed to incubate at 37˚C and 5% CO 2 for an
additional 72 hours. After 72 hours MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide)
dye (2mg/mL) was added to each well and incubated at 37 ˚C and 5% CO2 for 4 hours. Dye and media
were aspirated and DMSO was added to plate and placed on a rocker at room temperature for 10min.
Plate was then read at 570nm. Treated wells were all compared to DMSO control wells to calculate
percent growth inhibition and the IC50 was calculated using Graphpad (log(inhibitor) vs growth inhibition).
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Soft Agar Clonogenic: A base layer consisting of 1mL 1% Agar in RPMI-1640 was set and allowed to
cool to room temperature. A top layer was then added containing 500µL 0.5% agar in RPMI-1640 and
cells at indicated concentration on figure legend. Once agar had solidified at 37˚C, 500µL of RPMI-1640
culture media was added to the top. Plates were incubated for 14 days and were then stained with 0.01%
Crystal Violet and imaged. Images were then quantified using ImageJ.
Cellular Thermal Shift Assay: PC-9 cell line (9 million cells) were incubated with either 0.5% DMSO
control or T151742 at 100µM for 1hr at 37˚C. Cells were aliquoted at 1 million cells per pcr tube in PBS
and heated in Bio-Rad T100 thermal cycler at indicated temperatures (RT, 46˚C, 48˚C, 50˚C, 52˚C, 54˚C,
56˚, 58˚C, and 60˚C) for 3 minutes and aggregation temperature was determined by western blot
analysis. The CETSA Protocol was adapted from Jafari et al

45.

ERO1α antibody (santa cruz Cat# sc-

365526), ERO1β (proteintech Cat #11261-2-AP), and LSD-1 (cell signaling Cat#2139S). Secondary
antibodies used for detection include anti-rabbit IgG (Jackson laboratories Cat# 111-035-003) and antimouse IgG (Jackson laboratories Cat# 115-035-003). Substrate used for western blot detection was
ECL-A/ECL-B (Thermo Fisher CAT# 32209). All western blot images and analysis was completed using
the Amersham imager 680.
Biacore Analysis: Affinity analysis was carried out using a Biacore T200 instrument (GE Healthcare Life
Sciences and analysis was performed at Creative Biolabs, Shirley, NY). Briefly, ERO1α protein was
directly immobilized on the chip (Serie S-type CM5) using an amine coupling kit (GE Healthcare Life
Sciences). The protein was diluted into was diluted into 50 μg/ml with the immobilization buffer. The CM5
sensor surface was activated using 400 mM EDC and 100 mM NHS, injected at a flow rate of 10 μl/min,
with a contact time of 420s. ERO1α (50 μg/ml) was injected into FC2 at a flow rate of 10 μl/min. The
amount of ERO1α immobilized was about 10000 RU. Then, cholamine was injected for blocking at a flow
rate of 10 μl/min, with a contact time of 420s. T151742 was serially diluted with the running buffer to give
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a concentration of 100, 50, 25, 12.5, 6.25, 3.125, 1.563, 0 μM. Data analysis was performed on the
Biacore T200 computer and with the Biacore T200 evaluation software.
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3.1.8 Figures:

Graphical Abstract: T151742 binds allosterically to ERO1α and inhibits PC-9 Cancer cell growth
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Figure 1. T151742 is the most potent aurone and is two-fold more potent compared to EN-460
Purified human ERO1α (0.0625mg/mL) and purified human PDI (0.0625mg/mL) were incubated with
increasing concentrations of EN-460, T151742, T151688 or T151750. Each data point shown is the
average ± S.D (N=3 independent experiments and performed in triplicates). ****p<0.0001 by Two-way
ANOVA.
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Figure 2. Structures of the compounds evaluated for ERO1α enzyme activity.
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Table 1: Inhibition of ERO1α enzyme activity, reported as percent inhibition compared to vehicle
control. Shown is the average of N=3 ± S.D.
Compound

% inhibition (10µM)

Classification

T151742

55.31 ± 0.98

Aurone

T151688

40.46 ± 7.32

Aurone

T151750

48.60 ± 4.68

Aurone

SR-F-114

28.62 ± 5.57

Aurone

SR-F-115

27.48 ± 1.82.

Aurone

SR-F-125

20.73 ± 4.92

Aurone

SR-F-126

38.74 ± 1.56

Aurone

SR-F-127

33.40 ± 2.72

Aurone

SR-F-128

37.86 ± 2.42

Chalcone

SR-F-129

26.75 ± 1.44

Chalcone

SR-F-130

27.26 ± 3.16

Chalcone

SR-F-131

24.16 ± 0.52

Chalcone
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Figure 3. Electrostatic surfaces of compounds. Surface-electrostatic potential differences are
noticeable on the aurone and Calchone derivatives as compared to the ERO1α inhibitor EN-460, with
T151742 showing stronger correlation. Blue shows positive charge areas, and red shows negative
charge areas.
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Figure 4: T151742 binds directly to ERO1α and acts as a non-competitive (mixed) inhibitor. A.)
Purified human ERO1α (0.0625mg/mL), varying concentrations of purified human PDI (0.25µM, 0.125µM,
0.0625µM, 0.03125µM, and 0.5% DMSO), and varying concentrations of T151742 (100µM, 75µM, 50µM,
25µM, 10 µM, 0.1 µM and 0.5% DMSO) were assayed using amplex red assay to quantify enzymatic
activity. B.) The Lineweaver-Burk plot produced from taking the double reciprocal (1/[PDI]) vs
(1/[T151742]). C.) Surface Plasma Resonance demonstrates binding of T151742 directly to ERO1α (Kd
=31.4 µM).
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Figure 5. Docking studies of ERO1a inhibitors. The crystal structure of the active ERO1α (3ahq.pdb)
with the co-factor FAD was used for binding studies. A.) T151742 is shown docked with optimal hydrogen
bonding of the 6-hydroxyl to GLN93 and the 3-ketone to GLY138; B.) Loss of the 6-hydroxyl in T151688
led to a decrease in binding; C.) Loss of the 4-dimethylamino leads to reposing with GLY138 bond not
forming compared to T151742.
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Figure 6: CETSA assay validates target engagement of T151742 towards ERO1α and proliferation is
partially dependent on ERO1α expression by MTT assay in PC-9 cells. A.) PC-9 Cells were subjected to the
cellular thermal shift assay in the absence or presence of T151742. Upon addition of T151742, Tagg was
quantified for ERO1α, ERO1β, and LSD-1. Quantification of the average of n=3 independent experiments based on
western blot analysis for ERO1α, ERO1β, and LSD-1. The dashed line (- - -) line represents the cut-off point at
10% which was used to define our aggregation temperature (Tagg) of individual proteins. B.) MTT viability assay
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comparing potency between ERO1α inhibitor EN-460, T151742, and T151742 derivative SR-F-114, revealing SRF-114 is about two-fold less effective in vitro versus T151742 and EN-460 in the PC-9 non-small cell lung cancer
cell line. Combined n=3 independent experiments performed in quadruplicates*** p <0.001 by one-way ANOVA.
C.) Validation of ERO1α knockout in the PC-9 cell line utilizing CRISPR. D.) Two CRISPR deleted ERO1α clones
were subjected to treatment of T151742 as well as the non-targeted control PC-9 cell line. Cellular viability was
determined by MTT assay. n=3 independent experiments performed in quadruplicates. **** p<0.0001; by two-way
ANOVA.
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Figure 7: Soft agar clonogenic assays demonstrates T151742 is more potent compared to EN-460 and
ERO1α knockout clones are resistant to T151742 treatment. A-B.) 1000 cells/well were plated in a 12-well
plate in triplicate with either 0.5% DMSO, T151742, or EN-460 and allowed to form colonies for 14 days. Colonies
were subsequently stained with 0.01% Crystal Violet, imaged, and quantified using ImageJ. C-D.) 1500 cells/well
were plated in a 12-well in triplicate with either 0.5% DMSO or T151742 and allowed to form colonies for 14 days.
Colonies were stained with 0.01% Crystal Violet, imaged, and quantified using ImageJ.
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Supplemental Figure 1: Inhibitors that covalently modify FAD do not inhibit Ero1a activity.
The MOA inhibitor Tranylcypromine and LSD-1 inhibitor IV mechanistically inhibit LSD-1 via
covalent modification of FAD and were used to generate a concentration response. . Experiments
were performed in triplicates and shown is the mean and standard deviation of three independent
experiments.
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Supplemental Figure 2: LSD-1 retains demethylase activity against dimethylated lysine Nterminal tail of histone 3 (H3) upon treatment with T151742. T151742 was used to generate
a concentration response. As shown, T151742 did not inhibit LSD-1 demethylase activity at
concentrations ≤ 25µM using the LSD-1 inhibitor screening assay kit (Cayman chemical Item No:
700120). Experiments performed in triplicates and shown is the mean and standard deviation of
three independent experiments.
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Supplemental Table 1: IC50 values for T151742 were determined by MTT assay using a nonlinear regression. Cancer cell lines were more sensitive to treatment with T151752 versus
normal lung epithelium. IC50’s reported are averages of three independent experiments and
were performed in quadruplicates.
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CHAPTER 4.1.0: ERO1α Promotes Clonogenicity and Tumorigenesis Through Secretion of LAMC2
Brennan D. Johnson
4.1.1 Abstract:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounting for ~85%
of all lung cancer cases. Lung adenocarcinoma is one subtype of NSCLC and accounts for 50% of all
lung cancer cases. Recently, ERO1α has been reported to be a poor prognostic indicator in multiple
cancer types, including lung cancer, but it has not been studied in EGFR driven lung adenocarcinoma.
ERO1α is an endoplasmic reticulum lumen membrane bound protein responsible for protein folding of
transmembrane and secretory proteins. Here we were able to determine that CRISPR depletion of
ERO1α did not affect total EGFR levels or autophosphorylation levels (p-EGFR), decreased clonogenicity
5.87 fold on average in PC-9 cell lines (PC-9 Control = 210.1 ± 41.4, PC-9 ERO1α-/- C1= 31.4 ± 12.6,
PC-9 ERO1α-/- C2 = 41.6 ± 24.0), decreased clonogenicity in HCC4006 4.7 Fold on average (HCC4006
control = 667.4 ± 62.9, HCC4006 ERO1α-/- C1 = 129.9 ± 51.3, HCC4006 ERO1α-/- C2 = 156.2 ± 56.0).
However, upon addition of conditioned media from the respective control cell line but not from the
knockout resulted in reversal of clonogenicity. Publicly available CPTAC data revealed LAMC2
expression correlated with ERO1α expression. LAMC2 expression was found to be depleted in
conditioned media in both knockout cell lines compared to controls, but LAMC2 levels did not change
intracellularly, recapitulating what is seen in patient samples from CPTAC. Lastly, we were able to
determine that ERO1α-/- resulted in a significant increase in overall survival in SCID-Beige animals (PC-9
Control OS = 100 days, PC-9 ERO1α-/- OS = 154 days, p-value = 0.0045) and had a significant decrease
in overall tumor volume. These results provide evidence that ERO1α promotes tumorigenesis, stemness,
and tumorigenesis through LAMC2 axis.
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4.1.2 Introduction:
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer and accounts for
85% of all lung cancer cases1. NSCLC is divided into three sub-types with adenocarcinoma being the
most common accounting for 40% of all NSCLC cases1, 2. Lung cancer is the leading cause of cancer
related deaths and lung adenocarcinoma (LUAD) accounts for approximately 50% of all reported lung
cancer cases3. In recent years, precision medicine has made progress and treatments have evolved from
traditional chemotherapies toward personalized targeted therapies4-6. Lung Adenocarcinoma is one of the
most frequently mutational driven tumors; typically, harboring mutations in either Epidermal Growth
Factor Receptor (EGFR) tyrosine kinase domain (exon 19 deletion, L8585R, or T790M), or Kirsten Rat
Sarcoma (KRAS) G12C5, 7-15. Targeted therapies have been designed to target these EGFR mutations 1, 911, 16-22.

Despite these targeted therapies showing promising results, in the beginning, many patients will

relapse and become resistant to targeted therapies towards EGFR. Immunotherapy development has
led to a paradigm shift in cancer treatment as immunotherapies have the advantage of high efficiency,
long duration, and low toxicity23. Immunotherapies have become the standard of care recently for lung
adenocarcinoma for those with PD-1/PD-L1 high tumors. However, widespread usage of immunotherapy
is limited, and drug resistance is being increasingly reported 23-25. As a result, identification of new targets
or biomarkers to enable patient selection is still needed.
Endoplasmic Reticulum oxidoreductase-1α (ERO1α) is encoded on chromosome 14 and
considered to be the primary source in the endoplasmic reticulum (ER)26-28. ERO1α is an ER luminal
localized glycoprotein which favors disulfide bond formation via selective oxidation from protein disulfide
isomerase (PDI)23, 26. ERO1α is responsible for catalyzing disulfide bond formation of nascent
polypeptide substrates via electron transfer through protein disulfide isomerase (PDI) using FAD as a
cofactor to transfer electrons to molecular oxygen29-31. ERO1α is known to be responsible for the folding
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of secretory and transmembrane proteins by oxidative folding mechanisms with PDI. ERO1α is tightly
regulated via post translational modifications such as phosphorylation32, regulatory disulfide bridging
between Cys94-Cys99 allowing for nucleophilic attack on bridged cysteines of Cys394-Cys397, allowing
for nucleophilic attack and electron transfer onto the FAD ring which can further transfer electrons onto
molecular oxygen, and through N-glycosylation of specific asparagine residues located at Asp280 and
Asp38430. The electron transfer through disulfide bridges within ERO1α ultimately transfer electrons to
molecular oxygen producing hydrogen peroxide as an intermediate27, 33 Hydrogen peroxide intermediates
can normally be dealt with by endogenous peroxidases, but if not dealt with properly, buildup of peroxides
can lead to increased ER stress34. Cancer cells typically have increased ER stress in comparison to
normal cells and this increased ER stress can be seen more commonly in secretory tumors such as lung,
breast, multiple myeloma, and pancreatic35-38. ERO1α plays a critical role in ER homeostasis, via PDI
interaction to aid in protein folding, and has recently emerged as a key player in aiding in the tolerance of
cancer cells to handle ER stress39. ERO1α dysfunction critically effects multiple disease states, and has
recently been shown to promote cell migration, invasion, and metastasis in several cancer types,
including multiple myeloma, breast, hepatocellular carcinoma, diffuse large B-cell lymphoma, and head
and neck squamous cell carcinoma40-47. ERO1α molecular interactions and oxidation with PDI have been
well established48, 49. Despite multiple reports of ERO1α being a poor-prognostic indicator in multiple
cancer types, including lung adenocarcinoma, the mechanism by which ERO1α promotes lung
adenocarcinoma tumorigenicity, progression, and or metastasis has not been established. ERO1α has
previously been shown to play a role in tumorigenesis in multiple cancer types; however, its’ role
clonogenicity and tumorigenesis in lung adenocarcinoma has not yet been established. Although ERO1α
has been shown to play a role in these cancers, a mechanism for how it promotes tumorgenicity has also
not been hypothesized. Here, we sought out to determine the role ERO1α has in clonogenicity,
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tumorigenicity, and the mechanism by how it promotes these tumorigenic properties in EGFR driven lung
adenocarcinoma.
4.1.3 Materials and Methods:
Cell Lines:
HCC4006 cell line was obtained from American Type Culture Collection (ATCC) and was grown in
RPMI-1640 supplemented with 10%FBS and 1%P/S at 37˚C and 5% CO 2. PC-9 Cell line was obtained
from Sigma Aldrich and was grown in RPMI-1640 supplemented with 10%FBS and 1%P/S at 37˚C and
5% CO2. Both cell lines were mycoplasma tested every 6 months and subjected to STR testing every 6
months for cell line validation.
Clonogenic Assay:
Soft Agar Clonogenic: Using a 12-well plate, 1mL of 1% high-melting temperature agarose was added to
each well as needed to form a base layer. This layer was placed at 37˚C for approximately 1 hour and
allowed to solidify. Cells were then counted, resuspended in respective media containing 0.5% highmelting temperature agarose, as mentioned in figure legend, and seeded at 500cells/well in appropriate
wells; place in incubator for 2 hours at 37˚C to allow for top layer containing cells to solidify. Next, 500µL
of appropriate media was added to the top of respective wells. Fresh, respective media was added every
4-5 days and colonies were allowed to form for ~14 days. Upon end point, colonies were stained with
0.01% Crystal Violet, containing 20% methanol, overnight at room temperature, imaged on the Olympus
MVX microscope, and colonies were quantified using ImageJ.
Plastic Clonogenic: Using a 12-well plate, the respective cell line as mentioned in the figure legend, was
seeded at 50cells/well containing 2mL of respective media, as mentioned in figure legend. Fresh
respective media was replaced every 3-4 days and colonies were allowed to form for ~12 days. Upon
completion, media was aspirated from all wells and colonies were stained using 0.01% Crystal Violet,
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containing 20% methanol, at room temperature overnight. Next day, colonies were washed three times
with PBS, imaged using the Olympus MVX Microscope, and colonies were quantified using ImageJ.
Cell Lysates:
All cell lines were seeded at 500,000 cells/plate in a 10cm dish and allowed to incubate for 48
hours. After 48 hours, 3mL of trypsin was added for ~5min, neutralized with 7mL of media, and spun at
1000rom for 5 min. Media and trypsin were aspirated off the top, washed twice with PBS, and suspended
in 10µL of 1x RIPA. Lysates were placed on ice for 30min, then spun at 12,000 x g for 20min at 4˚C.
Supernatant was collected and used for further experiments.
Western Blot Analysis:
All cell lysates in RIPA were subjected to a BCA assay for protein quantitation. Samples were
made based on BCA assay and loaded onto a Bolt 4-12% gradient bis-tris gel (Cat #NW04125BOX
Invitrogen). Gel was run at 30V for 1 hour and then 100V for 1.5 Hours. Next, a PVDF membrane as
activated in 100% methanol for 2 minutes, followed by transfer from bis-tris gel onto membrane for 2.5
hours at 70V. Membrane was then blocked using 5% non-fat milk in TBST for 1 hour at room
temperature, washed 3x 10min each with TBST and then primary antibody as stated was added
overnight at 4˚C. Next day, the membrane was washed for 3x at 10 minutes each with TBST, followed by
addition appropriate secondary antibody at a 1:5000 dilution in 5% non-fat milk in TBST for 1 hour at
room temperature. The membrane was then washed 3x in TBST for 10min each, developed using ECLA/ECL-B reagent mixture (CAT #32106 Thermo Fisher) and imaged on the Amersham 680 (A680)
imaging system. All western blots were also quantitated using this imaging system via rolling ball method.
Protein Precipitation:
Cell line as specified in the legend was seeded at 1 million cells/plate in a 10cm dish in serum free
media. Media was collected after 48 hours; 3mLs were subjected to protein precipitation via acetone. 3x
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volume of ice-cold acetone was added and placed at -20 for 2 hours. After 2 hours visible whitish tint
flakes are visible in the tube. The precipitate containing acetone was spun at 4,500 x g for 20min at 4˚C.
supernatant was aspirated, and pellet was resuspended in 1% SDS in H 2O, sonicated and incubated on
ice for 45 min. After incubation, the samples were spun again at 12,000 x g for 10min at 4˚C, to get rid of
any insoluble proteins, supernatant was collected, and these samples were subjected to western blot
analysis.
Animal Study:
2 million cells of either PC-9 control cell line or PC-9 ERO1α-/- cell line were injected via tail vein
into SCID-Beige mice. Mice were euthanized based on end points established by IACUC protocol.
Weights were taken twice a week as well as daily health checks. Upon euthanasia, Lungs, Brain and
Liver were taken, fixed in formalin for 24 hours, switched into 70% ethanol for 48 hours, and then
subjected to paraffin embedding. Hind legs were also taking at euthanasia, fixed in formalin for 24 hours,
then decalcified before paraffin embedding.
Formalin Fixed and Paraffin Embedded (FFPE) Tissues:
Hematoxylin & Eosin (H&E): Lung Tissue that was FFPE were cut on a microtome in 4µM
sections, floated in a water bath, placed onto a positively charged slide, and allowed to dry at 37˚C
overnight. After drying, each slide was subjected to de-paraffination through warm xylene and ethanol
washes. Lung tissue was then stained in hematoxylin for 35 seconds, washed thoroughly in H 2O,
followed by an ethanol wash. The tissue was placed in Eosin for 2 minutes, washed thoroughly with
water, followed by ethanol, and then placed in xylene again until cover slipped. Once cover slipped, the
full slide was scanned using the Olympus Slide Scanner at 20x. Images were then placed into ImageJ
using bio-import formats, and tumor margins were outlined in a blind and unbiased fashion.
Enzyme Linked Immunosorbent Assay (ELISA):
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A sandwich-based one-step human LAMC2 ELISA kit (ab282301) was purchased from Abcam
and manufacturer’s instructions were followed.
Publicly Available Datasets:
198 EGFR driven Non-Small Cell Lung Cancer Adenocarcinoma RNA-Seq samples from the
GSE81089 was downloaded and separated by ERO1α expression. The Top quartile and the bottom
quartile in terms of overall survival were used. A Pearson Correlation on Mass-Spectrometry from EGFR
driven Non-Small Cell Lung Cancer Adenocarcinoma patients were used to determine proteins
associated with ERO1α tumors.
Proliferation Assays:
PC-9 or HCC4006 control and ERO1α-/- clones were seeded at 30,000 cells/well in a 6-well plate,
allowed to adhere overnight, and cells were counted every 24 hours by trypan blue exclusion. Dataset
was performed in triplicate and shown in the combined average ± S.D. for n=3. Doubling times were
calculated using a non-linear regression curve fit (doubling-time) in graph pad.
Conditioned Media Collection:
1 million cells of the respective cell line as described in the figure legend was plated in a 10cm
dish containing serum free media. Cells plated in serum free media were incubated for 48 hours at 37˚C
and 5% CO2. After 48 hours, the media was aspirated from the plate, placed into a 15mL conical tube,
and centrifuged at 2500 RPM to pellet any cell debris in the media. The supernatant was removed and
placed in a fresh 15mL conical tube. The media was then frozen at -80˚C for a later use.

Tumorsphere Formation Assay:
Methyl Cellulose (MethoCult Cat# H4100, Stem Cell Technology) was purchased and a 1% stock
was made in DMEM-F12 Medium (with P/S). Stocks were stored at -20˚C for later use. 20ng/mL bFGF,
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B27 Supplement (50x), and 20ng/mL EGF was supplemented for growth. 3-5 x 105 per sample was
embedded in the methyl cellulose and plated in triplicates. Cells in methylcellulose were plated in a 24well ultralow attachment plate. PBS was added to corner wells to maintain humidity and spheres were
allowed to form for 2-weeks. After 2-weeks, plates were imaged on the EVOS (life technologies) and
quantitated using ImageJ software.
4.1.4 Results and Discussion:
Previous literature suggests ERO1α is a poor prognostic indicator in multiple cancer types,
including multiple myeloma, breast, hepatocellular carcinoma, and head and neck 40-47, 50. Though ERO1α
has been reported to be a poor prognostic indicator in lung cancer, it has only been reported in KRAS
driven Non-Small Cell Lung Cancer (NSCLC)51, 52. Here we sought out to determine the effect ERO1α
has in EGFR driven NSCLC and the mechanism by which it promotes tumorigenesis. First, we were able
to create two ERO1α knockout (ERO1α-/-) clones in two distinct exon 19 deleted EGFR driven NSCLC
cell lines using CRISPR Cas9 lentiviral delivery (Fig 1A, 1B). Since ERO1α is responsible for the folding
of secretory and transmembrane proteins we performed a western blot to determine if there were any
differences in total EGFR and active (p-Y1068) EGFR in our ERO1α-/- cell lines in comparison to our
control cell lines and found there were no significant differences (Fig 1C, 1D). Lastly, ERO1α has been
shown to promote proliferation and migration in cholangiocarcinoma 53, thus we sought to determine if
there was a difference in doubling times of the two ERO1α-/- clones in comparison to the respective
control cell line. It was found that there was no difference in doubling times between the ERO1α -/- clones
in comparison to the controls by one-way ANOVA, and the doubling times calculated for the parental cell
line match previously reported value54 (Fig 1E, 1F).
Clonogenic phenotype can be rescued via conditioned media and ERO1α knockouts are less stem like:
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Previous literature reveals that ERO1α plays a role in clonogenicity and tumorigenesis, but the
mechanism by how ERO1α promotes these factors remain unknown. We were able to determine that
CRISPR deletion of ERO1α (denoted ERO1α-/-) resulted in decreased overall clonogenicity in both PC-9
and HCC4006 cell lines (Fig 2A, 2B). Interestingly, we were also able to determine from these studies
that the addition of conditioned media from the control cell line was able to partially rescue the PC-9
ERO1α-/- cell line, and completely rescued the HCC4006 ERO1α-/- cell lines (Fig 2C,2D). In addition, we
were able to diminish the effect of the conditioned media rescue in both PC-9 and HCC4006 cell lines
upon heat denaturing the conditioned media (Fig 2A, 2B). To determine if the rescue from conditioned
media was ERO1α specific, we also collected conditioned media one of the ERO1α-/- cell lines and were
able to determine that addition of conditioned media from either ERO1α -/- cell lines did not promote
rescue of colony formation (Fig 2C, 2D). Since heat denaturing resulted to similar results as normal
media, we decided to collect conditioned media after treatment with an exosome inhibitor GW4869 to rule
out exosomes as a possible mechanism of reversing the phenotype seen. First, we were able to
determine upon treatment with the exosome inhibitor we observed a ~50% decrease in exosome total
numbers in HCC4006 control cell line after treatment with 20µM GW4869 (supplemental figure 1A). Upon
50% depletion of exosomes from conditioned media, we saw no change in overall clonogenicity upon
addition of conditioned media collected from GW4869 treated cells. Together these data suggest
exosomes are not playing a role in the clonogenicity differences observed (Supplemental figure 1B).
Decrease in clonogenicity suggests that ERO1α may be playing a role in the stem cell population so we
performed a tumorsphere assay using methyl cellulose to determine if there was a decrease in stemness
in the ERO1α-/- knockout cell lines. PC-9 cells were grown in 1.9% methyl cellulose for 14 days, and
HCC4006 were grown in 1% methyl cellulose for 10 days, and it was found that both ERO1α-/- knockout
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clones in both cell lines had a decrease in colony formation, suggesting that the ERO1α -/- clones were
less stem-like than their respective control counterparts (Fig 3A-D).
Determination of cell line models in comparison to patient data:
Next, we wanted to determine the correlation between ERO1α expression and protein expression
in primary lung cancer patients. We were able to access mass-spectrometry data of lung
adenocarcinoma patient samples from the publicly available CPTAC data. A pearson correlation was
performed in respect to ERO1α to determine which protein’(s) are expressed with ERO1α in lung
adenocarcinoma patient samples (Figure 4A). A graph was generated from the pearson correlation to
represent proteins that were found to be highly correlative to ERO1α expression and is shown in Figure
4B. This data suggested that ERO1α expression correlated with proteins found present in the
extracellular matrix (ECM). From the pearson correlation we screened our cell lines for differences in the
ECM proteins (LOXL2, PLOD2, LAMC2, and FN-1). Interestingly, we were able to determine these
protein levels did not change intracellularly from whole cell lysates upon knockout of ERO1α in both PC-9
and HCC4006 cell lines (Figure 4C,D). However, despite no change intracellularly, LAMC2 was found to
decrease significantly in both ERO1α knockout cell lines upon protein precipitation from conditioned
media (Figure 4E, 4F). Upon protein precipitation using acetone, solubilization of proteins is often difficult.
To control for protein solubilization, we performed a one-step ELISA on conditioned media from control
and ERO1α-/- clones in both cell lines. From the ELISA we were able to conclude the results matched our
protein precipitation results in that LAMC2 was significantly decreased extracellularly (Figure 4G, H).
These combined results from CPTAC and our cell lines indicate that ERO1α plays a role in folding and/or
secretion of LAMC2. Bulk RNA-sequencing was also performed on PC-9 control and PC-9 ERO1α-/- cell
line and it was determined there were no differences in four ECM proteins (LAMC2, PLOD2, LOXL2, and
FN-1) found as hits from the CPTAC data (Supplemental Figure 2A-D). These results combined suggests
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LAMC2 secretion is regulated at the protein level, either through oxidative folding, or through the
secretory pathway. To answer this question fully further studies are needed.
Determination of ERO1α’s role in tumorigenicity
Giving that ERO1α knockout clones showed a decreased in clonogenicity and stemness, we
sought out to determine if knockout of ERO1α resulted in decreased tumor burden and increased overall
survival in SCID-Beige animals. Two million PC-9 control, or PC-9 ERO1α knockout cells were injected
by tail vein into SCID-Beige animals, and at defined end points, lungs, liver, brain, and hind legs were
obtained and imaged (Figure 5A). It was found during this study that PC-9 control mice were euthanized
more quickly than PC-9 ERO1α-/- containing animals, as PC-9 ERO1α-/- animals had significant increased
overall survival in comparison to the control group by log-rank test (Control OS: 100 days, PC-9 ERO1α
knockout OS: 154 Days, p=0.0045) (Figure 5B). Also, two PC-9 ERO1α-/- containing animals were still
alive at the endpoint of our study. Lungs that were formalin fixed and paraffin embedded (FFPE) were
subjected to staining via hematoxylin and eosin (H&E). H&E staining is shown in Figure 5C with the
images on the left being the H&E stain of a full section, and the image on the right being the same image
on the left, but with the tumor margins outlined using ImageJ. From the outlines, total tumor area was
found and graphed with each point representing an individual mouse point averaged over three serial
sections. These data indicate that PC-9 ERO1α-/- animals had significantly less total tumor area than the
PC-9 Control animals by students t-test (Figure 5D). In summary, these data indicate that knockout of
ERO1α resulted in decreased overall tumor burden and increased overall survival in SCID-Beige mice.
Thus, the in vitro and in vivo data support that ERO1α may be an attractive target for treatment of EGFR
driven lung adenocarcinoma.
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4.1.5 Conclusions:
First, we were able to obtain two ERO1α knockout clones in two independent EGFR driven
NSCLC cell lines. Originally, we thought that CRISPR deletion of ERO1α would affect EGFR expression,
as ERO1α is responsible for folding of membrane bound and secretory proteins. However, our data
indicates that ERO1α-/- does not affect total EGFR levels, nor does it affect autophosphorylation status of
EGFR. Also, literature suggests that ERO1α may promote cell cycle progression; however, our data
indicate that both knockout cell lines had no differences in proliferation in comparison to their respective
control cell line. Others have shown that ERO1α promotes clonogenicity, and we were able to show this
held true in both EGFR driven cell lines. Interestingly, we were able to rescue clonogenicity in our
knockout cell lines upon addition of conditioned media from our control cell line but not from our ERO1α
knockout cell line. Also, this rescue was diminished upon heat denaturing of conditioned media
suggesting some soluble factor is responsible. After eliminating exosomes as a possible source, we
obtained evidence consistent with patient data from publicly available sources that suggested that
LAMC2 may be responsible for the rescue in clonogenicity. Our data indicates that LAMC2 expression
does not change intracellularly in our ERO1α knockout cell lines but was found to be decreased in the
conditioned media from the ERO1α knockout cell lines in comparison to the respective control cell lines.
Lastly, we were able to determine that ERO1α expression had a poor prognosis in SCID-Beige animals,
and CRISPR knockout of ERO1α resulted in significantly decreased tumor burden in these animals.
When taken together, these results suggests that ERO1α is a poor prognostic indicator in EGFR driven
lung adenocarcinoma and may be promoting stemness and tumorigenesis through either folding and/or
secretion of LAMC2. However, further studies are needed to determine if ERO1α is promoting the folding
or the secretion of LAMC2 as this remains unknown at this time.
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4.1.8 Figures

Figure 1: Knockout of ERO1a does not affect total EGFR levels or p-EGFR status. A,B.)
Representative image of n=3 western blots revealing CRISPR deletion of ERO1a. C,D.) representative
n=3 western blots revealing knockout of ERO1a does not affect total levels of EGFR or p-EGFR is two
independent EGFR driven NSCLC cell lines. E,F.) Trypan blue exclusion assay reveals no significant
difference in doubling time for ERO1α knockouts in both PC-9 and HCC4006 cell line by one-way
ANOVA. Shown is the average n=3 ± S.D.

111

Figure 2: ERO1 knockout demonstrated decreased clonogenicity in comparison to control cell
line, can be rescued with addition of conditioned media from the control cell line, and evidence
suggests rescue occurs via a secreted soluble factor. A,B.) 500 cells/well were seeded in a 12-well
plate in respective media as described in the legend. Colonies were allowed to form for 7-10 days while
replacing respective media every 2-3 days, fixed in ice-cold methanol, stained with 0.01% crystal violet,
imaged on an Olympus MVX microscope, and quantitated using imageJ. C,D.) a 1% base agar layer was
added to a 12-well plate and allowed to solidify. 500cells/well were seeded in 0.5% agar and allow to
solidify at 37C for 2 hours. Agar was mixed with respective media as defined in the legend, and 500L of
respective media as defined in the legend was added to the top. Media was changed every 3-4 days,
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colonies were allowed to form for 14 days, fixed with ice-cold methanol, stained with 0.01% crystal violet,
imaged on the Olympus MVX microscope, and quantitated using ImageJ. * Denotes p<0.05 by two-way
ANOVA.
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Figure 3: ERO1α knockout clones reveals a decrease in total tumorsphere formation in both PC-9
and HCC4006 Cell lines : A,C.) Cells were seeded at 3-5000 cells per well in 1-1.9% methyl cellulose
supplemented with bFGF, EGF, and B29 supplement. Tumorspheres were allowed to form for 10-14
days before imaging. Images acquired on EVOS from life technologies at 4x showing representative field
of view. B,D.) Quantification of tumorsphere formation by imageJ. All experiments were performed threeindependent times in triplicates, and A,C are a representative image from one independent experiment,
and B,D are an average triplicate from one independent experiment. * denotes p<0.05 by one-way
ANOVA.
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Figure 4: Publicly available dataset CPTAC suggests LAMC2 Correlates with ERO1α expression;
PC-9 and HCC4006 ERO1α knockout cell lines show decrease LAMC2 secretion but no
differences intracellularly. A.) CPTAC, a publicly available lung adenocarcinoma patient data set
subjected to mass-spectrometry was utilized and a pearson correlation was performed. B.) The highest
correlated proteins from the pearson correlation represented as a bar graph with respect to ERO1α C,D.)
Representative n=3 of western blots on Whole Cell Lysates in PC-9 and HCC4006 cell lines. E,F.)
Representative n=3 western blots of protein precipitation from serum free conditioned media collected
after 48 hours. 1 million cells were plated in a 10cm dish in serum free media. 4mL of media was
precipitated via acetone and re-suspended in 150μL water containing 1% SDS. BCA was performed and
15µg was loaded per well. G,H.) ELISA was performed to quantitate total LAMC2 present between
control and ERO1α-/- knockout cell lines. ELISA was performed in triplicate and shown is the average ±
S.D. of n=3 combined results. * denotes p <0.05 by one-way ANOVA.
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Figure 5: ERO1α knockout results in decreased tumor burden and increased overall survival in
SCID-Beige mice: A.) 2 million PC-9 Control or PC-9 ERO1α knockout cells were injected via tail vein
into SCID-Beige mice. Shown is a representative image of a control lung (n=14) and a knockout lung
(n=13) taken on the Olympus MVX microscope at 0.63x. B.) Kaplan-Meyer curve showing that ERO1α
knockout increased overall survival compared to the control group. Significant by log-rank p = 0.0045. C.)
H & E was performed on 5 random lungs from each group selected by a random number generator. D.)
Tumor margins were drawn over the H & E images using ImageJ and tumor area was found. The
average area from three independent sections were taken for each mouse and is plotted. Each point
represents the average on three sections from each mouse. * Denotes p<0.05 by students t-test
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4.1.9 Supplemental Figures:

Supplemental Figure 1: Treatment with exosome inhibitor GW4869 inhibits exosome secretion by
~50% in both PC-9 and HCC4006 cell lines, and conditioned media from GW4869 treated cells
results in no change in clonogenicity. A.) HCC4006 control cell line treated with either 0.05% DMSO
or 20μM GW4869 for 48 hours in serum free media. Media was collected and run through the nanocyte
for exosome quantitation. * Denotes p < 0.05 by student’s t-test. B.) conditioned media from HCC4006
cell line treated with 20μM GW4869, 0.05% DMSO, or normal RPMI-1640 containing 10% FBS and 1%
P/S was used to determine differences in clonogenicity. Shown is the average of n=3 experiments
performed in triplicates ± S.D. Colonies were stained with crystal violet, imaged on the Olympus MVX
microscope and quantified using ImageJ. * Denotes p < 0.05 by two-way ANOVA.
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Supplemental Figure 2: bulk RNA-seq of PC-9 control and ERO1α-/- cell line reveals no differences
in four ECM proteins as found in CPTAC data. A-D.) RPKM plots for PLOD-2, LOXl2, LAMC2, and
FN1, the top four predictive markers from CPTAC public data set. No differences were found at RNA
level.
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Chapter 5.1.0 Future Directions:
5.1.0 Future Directions:
Determination of exosome involvement in clonogenic phenotype:
As outlined in chapter 4, we were able to deplete exosome numbers in the HCC4006 control cell
line by ~50% upon addition of 20µM GW4869. When comparing conditioned media with exosome
depletion to normal conditioned media there were no significant differences in the HCC4006 cell line.
However, despite no differences occurring in the HCC4006 cell line the same experiment needs to be
completed in the PC-9 cell line to conclusively rule out exosomes as not having a role in the clonogenic
phenotype seen. Interestingly, we have also generated preliminary data that suggests upon CRISPR
knockout of ERO1α results in significantly fewer total exosomes in comparison to the respective control
cell line (Figure 1A). Despite ERO1α knockout clones having decreased overall numbers of exosome,
their overall size remained similar to that of the parental cell line (data not shown). These data suggest
that ERO1α may be playing a role in the formation of exosomes or may be involved in the secretion of
exosomes in some way. This should be explored further to fully determine the role ERO1α has in the
formation/secretion of exosomes. To determine the mechanism of how ERO1α expression correlates with
total exosome numbers, it is important to determine where the secretory pathway involving exosomes is
being interrupted. Taken what is known about ERO1α folding secretory proteins we hypothesize that the
protein(s) involved in the formation of exosomes are not folded correctly resulting in less total exosomes.
There are a few main experiments proposed here that should be completed to answer this question.
Experiment one is to determine by which means under normal conditions that CD9, CD63, and CD81
(tetraspannins most commonly found within exosomes) are degraded. To do this, WT PC-9 and
HCC4006 cell lines should be treated with DMSO, bortezimib, or BAFA1 at multiple time points. CD9,
CD63, and CD81 should be western blotted for to determine which method (proteosome and/or
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lysosome) they are degraded. Once degradation method has been determined, the next experiment
should be performed to determine if one of these three proteins are changed in respect to ERO1α
expression. To answer this questions, western blots should be performed on control and ERO1α
knockout cell lines (PC-9 and HCC4006) to determine if these protein levels have changed under normal
conditions, and also upon treatment with bortezimib and or BAFA1 as done previously. If misfolded, we
would predict one or more of these three proteins would be decreased in the ERO1α knockout cell lines
and would be increased in the treatment group with the respective inhibitor of the pathway it is commonly
degraded by.
Also, publicly available data from EXOCARTA, reveals that ERO1α has been found in exosomes from
cancer patients and was identified through mass-spectrometry. Thus, we should precipitate exosomes
using ultracentrifugation, lyse them and perform a western blot to determine if ERO1α is present in the
exosomes from our NSCLC cell line models being used as data from EXOCARTA shows ERO1α present
in exosomes from lung cancer patients. If cell lines recapitulate what was found from patient samples, we
would expect to see ERO1α present in exosomes from our cell lines. Taken together, these results would
suggest that ERO1α has roles independent of its’ normal localization within the endoplasmic reticulum
and future studies should strive to determine these unknowns. There are a few main experiments that
should be performed to address this. Firstly, under the assumption that ERO1α is found to be expressed
in exosomes in our cell lines, I would utilize our CRISPR knockout cell lines and using lentiviral delivery
infect in wild-type ERO1α containing a 6x-his tag. Next, I would ensure that ERO1α is being expressed
within our cell lines by western blot, and confirm its presence again in exosomes via ultracentrifugation,
lyse the exosomes, and then perform western analysis to confirm its exogenous expression in exosomes.
Once presence intracellular and in exosomes has been confirmed, we should purify a large number of
exosomes using ultracentrifugation. After exosomes have been pelleted, a non-stringent lysis buffer ca
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be used to retain enzymatic activity. ERO1α protein can then be purified from this buffer using the 6x-his
tag present by using a Ni column, or Ni agarose beads. Purified ERO1α can then be subjected to our
established amplex red assay to determine if purified ERO1α-6x His tag contains its normal
oxidoreductase activity. If activity is maintained, then this would suggest it is present in exosomes to aid
in folding of other protein machinery present. If no oxidoreductase activity is present, it could be for one of
two reasons. 1.) ERO1α has other activity independent of its’ oxidoreductase function, or 2.) Purified
ERO1α activity was lost due to the purification process. If no oxidoreductase function was detected, then
further experiments would be needed for determination of why ERO1α function wasn’t found. For this I
would suggest using multiple lysis buffers during the purification process to determine which buffer is he
least stringent and does not cause linearization or denaturation. If multiple non-stringent lysis buffers still
result in no enzymatic activity this would suggest ERO1α has a role independent of its’ oxidoreductase
folding function that is currently unknown.
Determination of stem cell signature in NSCLC cell lines:
As outlined in Chapter 4, CRISPR knockout of ERO1α resulted in less tumorspheres in both PC-9
and HCC4006 cell lines. These results suggests that ERO1α plays a role in stemness. To identify stempromoting genes, we performed multiome single cell RNA-seq and single cell ATAC-seq (scRNAseq/scATAC-Seq) on 10,000 control and 10,000 ERO1α knockout cells from both PC-9 and HCC4006
cell lines (Figure 2A-B). Currently, t-SNE plots have been generated, as well as a heat map for
differentially expressed genes from G1 cell cycle, KI67low/TOP2αlow population, which we defined as the
quiescent/slowly dividing population (Figure 2B). t-SNE plots and heat maps have only been generated
currently for the PC-9 cell line with HCC4006 cell line currently in the bioinformatics pipeline. Though
current analysis was done so biasedly, these data set should be analyzed by cluster analysis unbiasedly
to define a stem cell signature common to both PC-9 and HCC4006 cell lines. This data set did reveal
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similar results to what was shown previously in Chapter 4 from the CPTAC proteomic data set, as
LAMC2, LAMA3, PLOD-2, and FN-1 were all found to be significantly decreased in our ERO1α KO cell
line in this low dividing population (Figure 2B). Though this data has yet to be fully interpreted, it could
potentially be used to identify a stem-like signature and changes in cell surface markers found in the
population would be a strategy to use fluorescently activated cell sorting (FACS) to determine differences
in ERO1α knockout cell lines versus their respective controls. This will determine differences in ERO1α
knockout cell lines in comparison to their control and give a definitive answer as to whether CRISPR
deletion of ERO1α leads to decrease in overall stemness in the cell line population from both PC-9 and
HCC4006 cell line models. Other than quantitation on differences in stem cell populations, FACS can be
used to obtain both control and ERO1α knockout cell lines with the stem cell signature defined by scRNASeq. This population can be isolated by FACS and both clonogenic and tumorsphere assays should be
performed. If the designated stem cell signature holds true, then we would expect no differences to be
observed in both assays as described in chapter 4.
Determination of soluble LAMC2 as being solely responsible for phenotype:
As shown in Chapter 4, LAMC2 levels were not changed at the RNA level, or intracellularly, but
was found to be significantly decreased extracellularly in the conditioned media collected. LAMC2 is the
rate limiting step in forming Laminin-5. Laminin-5 is a heterotrimeric protein composed of LAMC2,
LAMB3, and LAMA3. Though LAMC2 has been reported previously to function alone, it is well
characterized for being a part of Laminin-5. Currently, we have only tested levels of LAMC2, but still need
to probe for LAMB3 and LAMA3, both intra- and extracellularly to determine if what we have observed is
due solely to LAMC2 or if the phenotype we are seeing is due to decreased formation of Laminin-5.
Though LAMC2 can function as a monomer, there have been increasing reports of extracellular matrix
protein laminin-5 in promoting tumor growth and progression. Currently, we have purchased shRNA
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vectors for LAMC2, and lentiviral particles have been made for shNon-targeting and shLAMC2 that we
can use for infection into the PC-9 control and HCC4006 control cell line. Upon confirmation of
knockdown of LAMC2 intracellularly, LAMC2 needs to be confirmed to be reduced extracellularly as well,
by either ELISA or protein precipitation of conditioned media. Upon confirmation of decreased LAMC2
extracellularly, serum free conditioned media should be collected after 48 hours and used in both
tumorsphere and clonogenic assays. If soluble LAMC2 is solely responsible for the phenotype seen, then
we should not see rescue in the ERO1α knockout cell lines as previously seen. There is the exception
that decrease in LAMC2 may also result in decreased Laminin-5, which is why recombinant Laminin-5,
and recombinant LAMC2 should also be added to the clonogenic and tumorsphere assays individually
and combined determine if soluble LAMC2 or Laminin-5 is directly responsible for what we have seen
previously as described in chapter 4.
Determination of LAMC2 involvement In Vivo:
As described above and in chapter 4, our evidence suggests ERO1α regulates LAMC2 oxidative
folding or secretion, and LAMC2 is promoting clonogenicity and stemness in two independent EGFR
driven NSCLC cell lines. Also included in chapter 4 is an animal study that suggests ERO1α is a poor
prognostic indicator and promotes tumorigenesis. Despite H&E already being completed on these
tumors, IHC should also be completed looking at LAMC2 and Laminin-5 expression. If our animal model
recapitulates our cell line data, we predict that LAMC2 expression by IHC will be decreased
extracellularly in the ERO1α knockout model in comparison to the control ERO1α expressing model.
Currently, all lung tissues have been paraffin embedded, cut at 4µM, and placed on positively charged
slides. All that remains to finish are to deparaffinize, perform antigen retrieval, and perform IHC on lung
tissues probing for LAMC2, LAMB3, LAMA3, and Laminin-5. Based on previous results, we predict that
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LAMC2 will be reduced while expression of LAMB3 and LAMA3 will remain unchanged in the tumor
areas.
Determination of ERO1α’s role in immune modulation:
As described above in Chapter 2, ERO1α has been shown to aid tumors in immune invasion
through recruitment of myeloid-derived suppressor cells (MDSC’s) and through upregulation of immune
checkpoint blockade marker programmed death-ligand 1 (PD-L1). Our lab has shown that CRISPR
knockout of ERO1α leads to decreased clonogenicity but can be rescued upon addition of conditioned
media from an ERO1α expressing cell line. This data as well as previously reported data led us to
perform a 71-plex ELISA from Eve-Technologies to determine any differences in immune inflammatory
markers between our Control and ERO1α knockout cell lines. Interestingly, we found a few immune
modulatory markers that were changed between our ERO1α knockout cell lines in comparison to our
control cell lines (Figure 3A-H). Though not all 8 markers shown were significantly up or downregulated,
they need to be validated using a secondary method such as an ELISA, as a few of these markers have
been shown to play a role in immune suppression. If these markers are validated by secondary method
such as ELISA, then the next experiments would be to perform orthotopic injection of WT or ERO1α
knockout cells into an immune competent mouse (syngeneic). Collect tumors at end points, and collect
blood at different time points throughout tumor progression and monitor these cytokines that were
validated in cell lines.
Development on novel strategies towards targeting ERO1α, including combination approaches
for treatment of NSCLC:
As described in chapter 3, we have found a novel inhibitor of ERO1α inhibitor (T151742) from
naturally occurring sulfuretin derivatives. As described in chapter 2, ERO1α has been showed to be
involved in folding of Programmed Death-Ligand 1 (PD-L1) and increasing surface expression of PD-L1
124

in breast cancer cells. Thus, we predict that inhibition of ERO1α will lead to decreased PD-L1 expression
on lung cancer cells. This evidence along with the development of our novel ERO1α inhibitor T151742,
may prove useful for combination approaches. Therefore, future experiments should include an immune
competent mouse model such as C57BL/6 and or BALB c mice should be used to determine
efficaciousness of T151742 and pembrolizumab as single agents, as well as combination to determine if
this is a viable strategy towards targeting EGFR driven NSCLC. Lastly, we saw no change in resistance
to Osimertinib In Vitro upon CRISPR deletion of ERO1α. Thus, future studies should also aim to
determine the efficaciousness of T151742 and Osimertinib as both single agents and combination
therapies.
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5.1.1 Figures:

Figure 1: Total Exosome numbers are decreased in both ERO1α knockout clones in comparison to their
respective control. 1 Million cells were plated in serum free media and allowed to incubate for 48 hours. After 48
hours media was run through the nanocyte for quantification. Shown is an average n=3 ± S.D. and all samples were
performed in triplicate. * Denotes p<0.05 by two-way ANOVA.
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Figure 2: scRNA-sequencing of 10,000 cells from both PC-9 control and PC-9 ERO1α KO cell lines reveal a gene list
similar to the CPTAC proteome dataset. PC-9 ERO1α KO cell line show significant decreases in ECM markers such
as LAMC2, LAMA3, and FN-1. A.) scRNA Seq data was obtained via 10x genomics kit and sequenced. Results were
run through the cell ranger program and cluster analysis was performed. Shown is PC-9 Control and ERO1α KO
clustering. B.) Low proliferating cells were highlighted by cells present in G1 cell cycle that were also KI67 low and
TOP2α low expressing and a heat map of 100 DE genes Is shown comparing PC-9 ERO1α KO vs PC-9 control.
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Figure 3: 71-Plex of Immuno-modulatory markers reveals trends in 8 chemo/cytokines: Conditioned media was
obtained (n=3) after 48 hours in serum free media from PC-9 control, PC-9 ERO1α KO, HCC4006 control, and
HCC4006 ERO1α KO cell lines. Supernatants were sent to Eve Technologies for multiplex analysis. Shown is the
average n=3 ± S.D. Students t-test was performed between each cell line to determine significance. * Denotes
p<0.05
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Figure 4: ERO1α is degraded under normal conditions through the lysosome. A.) PC-9 control cell line was treated
with either 100nm BAFA1 or 10nm bortezimib. Results show that ERO1α accumulation occurs when treatment
with BAFA1, a lysosome inhibitor. These results suggests that ERO1α is normally degraded through the lysosome.
Data shown is a representative n=2. This should be repeated a third time in the PC-9 and be done in the HCC4006
cell line to make sure the data recapitulates in both cell line models.
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Abstract

Multiple myeloma (MM) cells demonstrate high basal endoplasmic reticulum (ER) stress and are typically
exquisitely sensitive to agents such as proteasome inhibitors that activate the unfolded protein response.
The flavin adenosine dinucleotide (FAD) containing endoplasmic reticulum oxidoreductin enzyme (Ero1L)
catalyzes de-novo disulfide bridge formation of ER resident proteins and contributes to proper protein
folding. Here we show that increased Ero1L expression is a prognostic of poor outcomes for MM patients
relapsing on therapy. We propose that targeting protein folding via inhibition of Ero1L may represent a
novel therapeutic strategy for the treatment of MM. In this report we show that treatment of MM cells with
EN-460, a known inhibitor of ERO1L, was sufficient to inhibit cell proliferation and induce apoptosis.
Furthermore, we show that cell death correlated in part with induction of ER stress. We also show that
EN460 inhibited the enzyme activity of Ero1L, with an IC50 of 22.13 μM, consistent with previous reports.
However, EN-460 was also found to inhibit other FAD-containing enzymes including MAO-A (IC50=7.91
μM), MAO-B (IC50= 30.59 μM) and LSD1 (IC50=4.16 μM), suggesting overlap in inhibitor activity and the
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potential need to develop more specific inhibitors to enable pharmacological validation of ERO1L as a
target for the treatment of MM. We additionally prepared and characterized azide-tagged derivatives of
EN-460 as possible functional probe compounds (e.g., for photo-affinity labeling) for future targetengagement studies and further development of structure-activity relationships.

Keywords: unfolded protein response; oxidative stress, flavin adenine dinucleotide
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Introduction
Multiple myeloma (MM) is a cancer of plasma cells that home to the bone marrow. Due to the highly secretory
function of plasma cells, MM cells are susceptible to high levels of ER stress. In fact, MM cells are uniquely
sensitive to proteasome inhibitors and these agents remain a mainstay of clinical treatment[1–4]. Although MM
patients will initially respond to proteasome inhibitors all patients relapse with resistant disease[5, 6]. Thus clinical
data continue to indicate that additional targets and therapeutic strategies are required to improve MM patient
outcomes. Recently, other groups have suggested that exploitation of the ER stress response can be targeted as a
mechanism to induce apoptosis in MM cells, by inhibition protein disulphide isomerase (PDI).[7, 8] Moreover,
blocking the proteasome with compounds such as velcade has become standard of care for the treatment of MM.[9]
Thus the clinical data indicate that inhibition of targets predicted to induce ER stress is a tractable strategy for the
treatment of MM
In this study, we focused on the he endoplasmic reticulum (ER) oxidoreductin Ero1L alpha, as one of two proteins
that contributes to the formation of disulfide bonds in proteins processed by the ER. Ero1L forms de-novo disulfide
bonds and the direct downstream target is PDI. In contract, PDI functions to oxidize downstream target proteins via
the formation of disulfide bonds (S-S) during the post-translational modification stage of protein processing in the
ER[10]. Ero1L is a Flavin adenosine dinucleotide (FAD) containing enzyme, where FAD is tightly associated with
the protein, and plays a role in the Ero1 catalysis mechanisms.
The formation of the disulfide bonds by Ero1L consumes oxygen that is used as terminal electron acceptor in the
reaction.[11] Recently the group of Blais et al. identified an Ero1L inhibitor during a high throughput screen (HTS).
The hit compound EN460 was found to inhibit the reoxidation of the protein enzyme,[12] however, the activity in
MM have not been investigated to date. Our focus in the long term is to target Ero1L for the treatment of cancers
susceptible to ER stress, and this current study was initiated to explore the effect of this chemical class on MM cell
lines.
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MATERIALS AND METHODS
Materials
EN460 was purchased from Tocris. Buffer components were purchased from commercial sources and were of
molecular biology grade.

Protein Expression and Purification
Human Ero1α (22–468) with hyperactivating triple mutation (C104A, C131A, and C166A) [insert citation: Inaba, et
al., EMBO Journal (2010) 29, 3330–334] DNA was synthnesized and subcloned (GeneArt/Invitrogen) into p15TVL vector (plasmid 26093, Addgene; Cambridge, MA, USA) using NdeI/NotI sites. ERO1α expression in E. coli
(BL21(DE3)RIL strain; OD 0.7) was induced with isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.1mM) for 20 h
at 18° C. Pelleted bacteria was lysed (50 mM Tris, pH 8.1, 300 mM NaCl, 10 μM FAD, , 0.5% Triton X-100) and
Ero1α isolated by affinity chromatography using an Ni-NTA column. His-tagged Ero1α protein bound on Ni-NTA
column was washed with 50 mM Tris, pH 8.1, 300 mM NaCl, 10 μM FAD, 20 mM imidazaole then eluted with
increased imidazaole (240mM) in wash buffer. Purified Ero1α protein underwent desalting to remove imidazaole
then oxidation with potassium ferricyanide (20mM) for 16 h at 4° C. A preparative Superdex 200 column (GE
Heathcare Life Sciences, Pittsburgh, PA, USA) was used to obtain a monomeric Ero1α fraction in 50 mM Tris, pH
8.1, 150 mM NaCl, 10 μM FAD. Concentration of purified hEro1α protein was determined with NanoDrop
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) at UV 280 nm.
Human PDI (18–479) DNA was synthesized and subcloned (GeneArt/Invitrogen) into p15TV-L vector and
expression induced in E.coli as described above. Pelleted bacteria was lysed with 50 mM Tris, pH 8.0, 300 mM
NaCl, 1 mM TCEP, 1% Triton X-100, 10 mM Imidazole, and DNase (20 ug/mL) for 1 h at 4°C. His-tagged hPDI
protein was isolated from lysate with Ni-NTA Agarose (Invitrogen, Carlsbad, CA, USA). His-tagged PDI bound NiNTA resin was washed five times with 50 mM Tris, pH 8.0, 300 mM NaCl, 1 mM TCEP, and 20 mM imidazaole
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and purified hPDI protein was eluted with wash buffer with 250 mM imidazaole. PD-10 Desalting Columns (GE
Heathcare Life Sciences) were used to remove high levels of imidazaole. Purified hPDI protein was concentrated
and small molecular weight impurities were removed with Amicon Ultra-15 Centrifugal Filter Unit, 10KDa cutoff
(EMD Millipore, Burlington, MA, USA) using 50 mM Tris, pH 8.0, 150 mM NaCl, and 1 mM TCEP buffer. The
concentration of purified hPDI protein was determined with NanoDrop spectrophotometer (UV 280 nm).

Amplex Red/Ero1α Catalytic Assay
Purified hyperactive human Ero1α (0.0625 mg/mL), HRP (50 μU/uL, EMD Millipore), Amplex Red (25 μM,
Invitrogen) were combined with range of concentrations of purified human PDI (0.250 – 0.008 mg/mL) and/or
Ero1α inhibitors (EN460 (EMD Millipore), PB-EN-10; 200 – 0.01 μM) in 50 mM sodium phosphate, pH 7.4 in a
384 well black microplate (Corning, Tewksbury, MA USA). Microplate was incubated for 30 min at 37° C;
Cytation 5 Cell Imaging Multi-Mode Reader (Ex 530, Em 590) (BioTek, Winooski, VT, USA) measured
fluorescence intensity.

Protein Thermal Shift Assay
To determine the protein stability, a differential scanning fluorimetry (DSF) study was done. SYPRO Orange
Protein Gel Stain (1X, Sigma-Aldrich, St. Louis, MO, USA), purified hEro1α or hPDI proteins (0.250 mg/mL), and
Ero1α inhibitors (EN460 or PB-En-10; 20 μM) were combined in 50 mM Tris, pH8.0, 150 mM NaCl in MicroAmp
optical 96 well reaction plate (Thermo Fisher Scientific). Melt curve reaction was run on Step One Applied
Biosystems real-time PCR system (Life Technologies). Fluorescent readings (target setting: ROX) were collected
every 1° C from 25° C to 99° C using a continuous ramp rate. Protein Thermal Shift Software v 1.3 (Life
Technologies) was used to analyze results. Melting temperatures (Tm) were generated from derivatives of melt
curves (Δ Fluorescence/Δ).
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FAD enzyme assays
Monoamine oxidase A and B enzymes was purchased from BD Biosciences. Enzyme activity was determined using
kynuramine metabolism by MAO-A and MAO-B as previously published. Fluorescence was determined using
BioTek Cytation 5 plate reader, 310/380 Ex/Em nm. LSD-1 activity was determined using a kit from Caymen
Chemicals according to the manufacturer’s specifications.

Molecular Docking Studies
The crystal structure of Ero1 was obtained from the RCSB Protein Data Bank access code: 3AHQ (hyperactive
form).[13] The protein structure was prepared for docking studies using MOE 2018 (www.chemcomp.com) to add
missing hydrogens and ionize the amino acid side-chains at pH 7.4. The FAD core structure was used to delineate
the binding pocket, followed by an standard induced fit docking protocol, as implemented in the DOCK program in
MOE 2018. The top docked poses were evaluated for specific ligand interactions with the protein.
The EN460 derivatives were prepared as shown in the Scheme 1. Pyrazolone 3 was synthesized as reported
previously.[14] Substituted furfuraldehyes 9 and 10 were synthesized by Suzuki coupling of aryl iodides 6 and
7[15] with furfural-boronic acid 8.[16] Knoevenagel condensation of the substituted furfuraldehyes (9 and 10) with
pyrazolone 3 using catalytic sodium acetate in acetic acid provided EN460 derivatives PB-10 and PB-11 in 93%
and 53% yields, respectively.

1. Chemistry
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All the chemicals were used as received unless otherwise stated. All solvents, solutions and liquid reagents were
added via syringe. All reactions were carried out under an inert nitrogen atmosphere unless otherwise stated. The
purifications were performed by flash chromatography using silica gel F-254 (230–499 mesh particle size). Yields
refer to isolated material judged to be ≥95% pure by 1H NMR spectroscopy following silica gel chromatography.
1H-NMR and 13CNMR spectra were recorded on a JEOL 400 MHz spectrometer using CDCl3 or DMSO-d6 as the
deuterated solvent. The chemical shifts (δ) are reported in parts per million (ppm) relative to the residual CHCl3
peak (7.26 ppm for 1H-NMR and 77.0 ppm for 13C-NMR) or DMSO 2.50 ppm for 1H-NMR and 39.5 ppm for
13C-NMR). The coupling constants (J) are reported in Hertz (Hz). IR spectra were recorded by using a PerkinElmer Spectrum 100 FT-IR spectrometer with diamond ATR accessory as thin film. Mass spectra were recorded
using electrospray ionization (ESI).

2. Preparation azidoiodobenzenes

2.1. 4-azidoiodobenzene (7)
A round bottom flask was charged with 4-iodoaniline (5, 3 g, 13.7 mmol, 1.0 eqv.) and water (15.2 mL, 0.90 M).
Concentrated HCl (2.5 mL 2.1 eqv.) was added to vigorously stirred reaction mixture in an ice-water bath. A precooled solution of NaNO2 (0.95 g, 13.7 mmol, 1.0 eqv.) in water (5.50 mL, 2.50 M) was added dropwise to the
reaction mixture, after which time the reaction mixture was stirred for 15 min. The solution of NaN3 (0.89 g, 13.7
mmol, 1.0 eqv.) in water (5.50 mL 2.50 M) was added dropwise to the reaction mixture while maintaining the
temperature in the ice bath, and then the reaction mixture was stirred an additional 20 min at 0 °C, then stirred at rt
for another 3 h. The reaction mixture was extracted with EtOAc (2×50 mL) and the aqueous layer was adjusted to
pH 8–10 with NaHCO3 before discarding. The combined organic solution was washed with water and brine and
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude azidoiodobenze derivative was
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further purified by flash column chromatography over silica gel with 0–5% ethylacetate/hexanes as eluent to afford
4-azidoiodobenze (7, 2.60g, 78%). 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.7 Hz, 2H), 6.77 (d, J = 8.7 Hz,
2H). 13C NMR (101 MHz, CDCl3) δ 140.06, 138.79, 121.14, 88.31.

2.2. 3-azidoiodobenzene (6)
3-azidoiodobenzene (6, 2.80 g, 69%) was prepared from 3-iodoaniline in a manner analogous to that described for
4-azidoiodobenzene. 1H NMR (400 MHz, CDCl3) δ 7.46 (ddd, J = 7.8, 1.6, 0.9 Hz, 1H), 7.41 – 7.32 (m, 1H), 7.06
(td, J = 7.9, 0.8 Hz, 1H), 6.98 (ddt, J = 8.1, 2.0, 0.9 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 141.33, 133.91,
131.04, 127.89, 118.39, 94.61.

3. Preparation of substituted furfuraldehydes

3.1. 5-(4-azidophenyl)furan-2-carbaldehyde (10)
To a vial containing 4-azidoiodobenzene (7, 0.50 g, 2.04 mmol, 1 eqv.), furfural-boronic acid 8 (0.37 g, 2.65 mmol,
1.30 eqv.), and bis(triphenylphosphine)palladium(II) dichloride (0.10 g, 0.10 mmol, 5 mol%) was added EtOH (1.00
mL), DME (0.61 mL), and 2M aqueous Na2CO3 (1.8 mL). The reaction mixture was heated in an oil bath at 65 °C
for 1 h. The mixture was diluted with H2O and extracted three times with ethyl acetate. The combined organic
layers were washed with brine, dried over Na2SO4, filtered and concentrated. The crude product was purified by
column chromatography (5–15% ethyl acetate/hexanes) to afford 5-(4-azidophenyl)furan-2-carbaldehyde (10, 0.25
g, 1.17 mmol, 56%): 1H NMR (400MHz, CDCl3) δ 9.64 (s, 1H), 7.82 (d, J = 8.6 Hz, 2H), 7.33 (d, J = 3.8 Hz, 1H),
7.16 – 7.02 (m, 2H), 6.81 (d, J = 3.7 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 177.20, 158.72, 152.03, 141.46,
126.95, 125.81, 119.68, 107.59.
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3.2. 5-(3-azidophenyl)furan-2-carbaldehyde (9)
5-(3-azidophenyl)furan-2-carbaldehyde (9, 0.25 g, 57%) was prepared from 3-azidoiodobenzene (6) in a manner
analogous to that described for 5-(4-azidophenyl)furan-2-carbaldehyde (10). 1H NMR (400 MHz, CDCl3) δ 9.67 (s,
1H), 7.58 (ddd, J = 7.8, 1.6, 0.9 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.33 (d, J = 3.8 Hz, 1H), 7.06 (ddd, J = 8.1, 2.2, 1.0
Hz, 1H), 6.87 (d, J = 3.7 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 177.34, 158.04, 152.21, 140.98, 130.57, 130.35,
121.72, 119.95, 115.59, 108.46.

4. Preaparation of pyrazolone 3

4.1. 2-chloro-5-hydrazinobenzoic acid hydrochloride
To a solution of 5-amino-2-chlorobenzoic acid (1, 2.50 g, 14.6 mmol) in concentrated HCl (10 mL) at 0 °C was
slowly added a solution of NaNO2 (1.21 g, 17.5 mmol) in water (5.0 mL) at a rate that maintained the solution
temperature below 5–10 °C. After stirring for 30 min, a solution of tin chloride dihydrate (8.20 g, 36.4 mmol) in
water (5.0 mL) and concentrated HCl (10 mL) was added a rate that maintained below 5–10 °C. The viscous
mixture was diluted with an additional 10 mL of concentrated HCl and 5.0 mL of water and stirred an additional 4 h
at 5–10 °C. The crude mixture was then filtered, and collected solids were recrystallized from hot water (60 mL) to
provide 2-chloro-5-hydrazinobenzoic acid hydrochloride (2, 1.5 g, 55%) 1H NMR (400 MHz, DMSO-d6) δ 10.50
(s, 3H), 8.68 (s, 1H), 7.58 – 7.25 (m, 2H), 7.13 (dd, J = 8.7, 2.8 Hz, 1H), 3.45 (s, 2H). 13C NMR (100 MHz,
DMSO-d6) δ 167.10, 145.11, 132.16, 131.60, 123.79, 118.80, 116.52.

4.2. 2-chloro-5-(5-oxo-3-(trifluoromethyl)-2,5-dihydro-1H-pyrazol-1-yl)benzoic acid (3)
To a solution of 2-chloro-5-hydrazinobenzoic acid hydrochloride (2, 0.75 g, 3.36 mmol, 1 eqv.) and ethyl 4,4,4trifluoroacetoacetate (0.49 mL, 3.36 mmol, 1 eqv.) in acetic acid (3.4 mL, 1.0 M) was added triethylamine (0.49
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mL, 3.36 mmol, 1 eqv.). The resulting mixture was heated at reflux for 24 h. The excess acetic acid was evaporated
under reduced pressure, resulting in viscous oil. The crude product triturated by addition of DCM, filtered, and dried
under vacuum to afford pyrazolone 3 (0.74 g, 72%). 1H NMR (400 MHz, DMSO-d6) δ 13.34 (s, 1H), 8.18 (d, J =
2.7 Hz, 1H), 7.94 (dd, J = 8.8, 2.8 Hz, 1H), 7.70 (d, J = 8.7 Hz, 1H), 5.98 (s, 1H), 3.39 (s, 1H).

5. Preparation EN460 derivatives PB-10 and PB-11

5.1. (E)-5-(4-((5-(4-azidophenyl)furan-2-yl)methylene)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1Hpyrazol-1-yl)-2-chlorobenzoic acid (PB-11)
To a solution of 2-chloro-5-(5-oxo-3-(trifluoromethyl)-2,5-dihydro-1H-pyrazol-1-yl)benzoic acid (3, 104.3 mg, 0.49
mmol, 1 eqv.) and 5-(4-azidophenyl)furan-2-carbaldehyde (10, 150.0 mg, 0.49 mmol, 1 eqv.) in acetic acid (0.98
mL, 0.5 M) was added catalytic amount of NaOAc (4.0 mg, 49 μmol, 0.1 eqv.). The resulting mixture was heated to
reflux for 3 h. The excess acetic acid was evaporated under reduced pressure, followed by trituration by addition of
a water-methanol mixture. The crude product was filtered and washed with water to afford PB-11 as a reddish solid
(127.9 mg, 52%) 1H NMR (400 MHz, DMSO-d6) δ 12.15 (s, 1H), 8.70 (s, 1H), 8.30 (dd, J = 11.1, 2.7 Hz, 1H),
8.10 – 7.94 (m, 1H), 7.92 – 7.46 (m, 6H), 7.22 (dd, J = 8.0, 2.4 Hz, 1H).

5.2. (E)-5-(4-((5-(3-azidophenyl)furan-2-yl)methylene)-5-oxo-3-(trifluoromethyl)-4,5-dihydro-1Hpyrazol-1-yl)-2-chlorobenzoic acid (PB-10)
PB-10 (231.0 mg, 93%) was prepared from 2-chloro-5-(5-oxo-3-(trifluoromethyl)-2,5-dihydro-1H-pyrazol-1yl)benzoic acid (3) and 5-(3-azidophenyl)furan-2-carbaldehyde (9) in a manner analogous to that described for PB11. 1H NMR (400 MHz, DMSO-d6) δ 13.66 (s, 1H), 8.30 (dd, J = 11.9, 2.7 Hz, 1H), 8.13 – 7.95 (m, 2H), 7.91 –
7.83 (m, 1H), 7.78 (s, 1H), 7.69 – 7.58 (m, 2H), 7.37 – 7.18 (m, 2H).
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MTT Assay
Cells were seeded at 15,000 cells per well in 96-well plate and cells are incubated with DMSO or increasing
concentrations of EN460, PB-10, and PB-11 (0.78, 1.56, 3.13, 6.25, 12.5 and 50 μM) for 72h. Afterwards, 50 μl of
MTT (2 mg/ml) was added to each well and incubated for 4h. The formazan crystals in viable cells were dissolved
by using dimethyl sulfoxide (DMSO, 50 μl per well). The absorbance of each well was measured using a microplate
reader (Spectramax 190, USA) at 570 nm. All the experiments were performed in triplicate.

Western blot analysis
U266 cells were incubated with DMSO or EN460 for 2, 4 and 8h and cell lysates were collected (n=3 independent
assays). Protein extracts was separated in 8–10% SDS-PAGE gel and transferred onto a PVDF membrane
(Millipore, MA) and incubated with 5% nonfat milk in tris-buffered saline with Tween 20 (TBST) buffer for 1 h at
room temperature. Membranes were then incubated for overnight at 4°C with different antibodies: p-EIF2alpha
(3597), ATF4 (11815) and ATF6 (65880) were purchased from Cell Signaling Technology (Boston, MA) and betaactin (A2228) was purchased from Sigma-Aldrich. Blots were then incubated with secondary anti-mouse or antirabbit HRP labeled antibodies (Jackson ImmunoResearch Laboratories, Westgrove, PA, USA) for 1h. The
membrane was developed and protein signals were detected using chemiluminescence (Amersham Imager 600,
GE).

Annexin V/propidium iodide (PI) double-staining assay
Apoptosis was measured by flow cytometry using Annexin V/PI double staining to detect apoptotic cells. U266
cells were treated with DMSO or EN460 for 18h. Cells were harvested and washed with ice-cold PBS and
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resuspended in 1X binding buffer containing Annexin V and PI for 15 min at 37°C in the dark. Stained cells were
quantified by flow cytometry. At least 10,000 cells were analyzed for each sample (n=3 independent assays).

MM Patient Cohort
Series GSE9782 was downloaded from the Gene Expression Omnibus (GEO). Gene expression data consists of
Affymetrix HG-U133A and HG-U133B GeneChip arrays. Normalized, processed data was used from GEO; array
processing is described in Mulligan, et al. There were 264 patients profiled, including 76 Dexamethasone-treated
and 188 bortezomib-treated patients. Two probesets are reported to detect Ero1L (218498_s_at and 222646_s_at).
We use 222646_s_at as it had the largest average expression (306.99101). Differences in outcomes (overall
survival) were determined by stratifying the patient population on median Ero1L expression (222646_s_at). A
Kaplan-Meier survival curve was generated based on these groupings, and a log-rank test was performed to assess
statistical significance.

Results and Discussion
In this study, we evaluated the role of Ero1L as potential drug target in MM. Additionally, we further evaluated the
Ero1L inhibitor EN460 as proof of principle for movement into novel chemotherapeutic space, and developed two
additional EN460 derivatives (PB-10 and PB-11) as a tool set to probe biological activity. To determine whether
Ero1L expression was a poor prognostic indicator for the treatment of MM we utilized a publically available data
set that was generated from several Phase II-III trials (024, 025, 039, 040) which either assessed Bortezomib or
compared Bortezomib to high dose dexamethasone treatment[17]. Briefly, patients were consented for genomic
analyses of pretreatment tumor samples. In GSE9782, all patients receiving bortezomib (n=188) were compared for
differences in outcome related to ERO1L expression levels. Kaplan-Meier estimates were calculated for overall
survival in the high (>median ERO1L expression) and low (<median ERO1L expression) groups. A log-rank test
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was used to assess significant difference in outcome, and a Cox regression of the dichotomous variable (high vs.
low) was used to estimate a hazard ratio and confidence interval. Patients had one or more prior therapies.
Correlations of high ERO1L alpha expression and poor outcome extended to both bortezomib and dexamethasone
treated patients (See Figure 1 p<0.01). Thus, ERO1L alpha may be a marker of drug resistance or tumor progression
independent of the mechanism of action of the drug. Collectively, these data suggest that ERO1L alpha is predictive
in the setting of relapsed MM patients and maybe a good marker for stratifying patients to receive novel therapies
versus additional standard of care agents.
Biological characterization of the Ero1L inhibitor [12] EN460 was performed in U266 MM cancer cells. As shown
in Figure 2, EN460 induces apoptosis in the MM U266 cells as detected by the percentage of Annexin V positive
cells. This finding correlates with the induction of ER stress as measured by induction of p-EIF2 alpha and
reduction of full length ATF6. However, considering the lack of specificity of EN460, novel probes are required to
further validate whether targeting Ero1L as a single target is sufficient to induce ER stress and cell death in MM
cells. Furthermore, we found that treatment with EN-460 of normal PBMCs was sufficient to induce cell death (data
not shown). Due to the lack of specificity of EN-460, it is difficult to assess whether the toxicity is due to on target
or off-target effects and thus supports the need to develop more specific ERO1L compounds, which do not inhibit
other FAD containing enzymes to enable pharmacological validation of the target for the treatment of cancer.
Considering the clinical data showing that high Ero1L expression levels are a poor prognostic indicator of survival,
the development of chemical probes targeting Ero1L are warranted to validate whether targeting Ero1L is a tractable
strategy for the treatment of multiple myeloma. To date few studies have focused on the identification and
development of novel Ero1L inhibitors. The first paper published on this topic identified the inhibitor EN460, which
inhibited the enzyme in the low micromolar range.[11] Ero1L and PDI work in concert to form the protein folding
via disulfide bonds.[13, 18] Figure 3 shows the docked Ero1-PDI protein-protein interaction site as determined via
docking using the Gramm-X protein docking server, showing the interaction between the transfer faces of the two
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proteins.[19] Since the crystal structure of Ero1L (hyperactive 3AHQ) does not have the full sequence we modeled
the extra loops with YASARA (www.yasara.com). The EN460 compound has poor solubility, which does not allow
for reaching >200 uM concentrations in vitro. To gain insight into the structural features important for interaction
with Ero1L we screened two derivatives: AK968 and AN968. AN968 was found to be marginally active (See
Supplementary Fig. 2), while the derivative AK968 was inactive. We concluded that the 3-carboxyalic acid group
closest to the pyrazole was an important feature since AN968 was less active than EN460, and removal of the
carboxylic acid group from AK968 resulted in complete loss of compound activity. We designed and prepared two
azide derivatives of EN460: PB-10 and PB-11. These probe molecules compounds were designed to increase
versatility through the inclusion of functionalizable handles (Scheme 1). Our hypothesis was that these EN460
derivatives would have similar activity as compared to EN460. Compound PB-10, the meta-azido isomer, was
comparable in solubility to EN460. On the other hand, the paraazido isomer PB-11 was less soluble in physiological
buffers (e.g. PBS pH 7.4) and therefore was not used for subsequent bioassay experiments. We characterized the
inhibition of Ero1L by EN460 and the azide derivative PB-10 (Figure 4A) by enzymatic and thermal shift assays.
Both EN-460 and PB-10 inhibited Ero1L enzymatic activity in a similar dose dependent manner (see Figure 4B).
The interaction between Ero1L and EN460 was further evaluated by thermal shift assay (Figure 4C–D). The protein
and ligand is co-incubated and heated where the increased loss of 3D structure (denaturation) allows for the
fluorescent probe SYPRO Orange to bind and fluorescence. A shift in melting temperature shows stabilization of
the protein and therefore binding to the protein. The Tm for Ero1L with addition of DMSO (2% DMSO vehicle
control 53.15 °C +/− 0.15 SEM) EN460 (55.86 °C +/− 0.3 SEM) and PB-10 (59.76 °C +/−0.27 SEM) was able to
shift the melting temperature indicating a stabilization effect on the Ero1L structure (Figure 4C–D). The Tm of PDI
was not significantly altered with the addition of EN460 (59.21 °C +/− 0.24 SEM) or PB-10 (57.67 °C +/− 0.11
SEM) compared to control (DMSO, 58.86 °C +/− 0.12 SEM) suggesting EN460 and PB-10 do not bind and
stabilize PDI (Figure 4E and 4F). Together these data indicate that neither EN-460 nor PB-10 shifted the PD1 melt
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curve, and enzymatic inhibition was due to binding Ero1Lα and not PDI (Figure 4E–F). Interestingly, the increase
in stability due to PDI/PB-10 interaction did not affect the activity of Ero1L in vitro. The IC50 determined by
enzymatic Amplex Red assay were similar between PB-10 (IC50 = 12.19 μM) and EN460 (IC50 = 12.74 μM).
U266 and MM1.S cells exposed to EN460 had IC50’s, of 10.1 μM +/−1.11 and 14.74 μM +/− 1.23 respectively,
compared to PB-10 (14.73 μM 14.73 +/− 1.1 and 18.76 μM +/− 1.06) (Table 1).
To date the full spectrum of EN460 activity for FAD containing enzymes have not been studied. Since Ero1L is an
FAD containing enzyme, several other FAD containing enzymes have been characterized as drug targets for the
treatment of a variety of diseases. To delineate the selectivity of EN460, we tested it against four classical FAD
containing enzymes, including monoamine oxidase A and B (MAO-A and MAO-B), as well as Lysine-specific
histone demethylase 1A (LSD1; lysine (K)-specific demethylase 1A (KDM1A)). Figure 5 shows that EN460
inhibited the FAD containing enzymes in the low microM range, IC50: Ero1 = 22.13 uM, MAO-A = 7.9 uM, MAOB = 30.59 uM, and LSD-1 = 4.16 uM. Both MAO-A and LSD1 have high sequence similarity so it was not
surprising to see inhibition at the same level for the two enzymes. Figure 6 shows the enzyme-inhibition kinetics,
with EN-460 inhibiting Ero1L in a competitive manner based on the analysis of the increased substrate PDI with
different combination of EN460 concentrations, resulting in a Km, which was increased, but the Vmax largely
stated the same. To gain insight into the different binding modes, molecular docking studies were performed.
EN460 bound to the FAD pocket of Ero1L through hydrogen bonding to TRP197 and ARG287, and hydrophobic
interactions between the aromatic groups and CYS397 and ARG287 (Figure 7). In the enzyme MAO-A, a hydrogen
bond with SER209 was predicted, while the aromatic ring of EN460 was sandwiched between the aromatic rings of
TRY407 and TRY444 (Figure 8). MAOB binding was achieved through aromatic interactions with no hydrogen
bonding predicted, which would account for the lower inhibition (~30 uM) (Figure 8). Lastly, the FAD containing
enzyme LSD1 was also docked with EN460, and found it docked through hydrogen bonding with VAL764 and an
aromatic interaction with ALA539 (Figure 9). Considering the close homology between MAO-A and LSD1 it not
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surprising that they share similar IC50 values, with LSD1 only slightly more inhibited by EN460. LSD1 is also
known as KDM1A and is a FAD demethylase, where it removes methyl groups from histone 3 protein H3K4me2/1
and H3K9me2/1. LSD1 has recently gained more attention as a possible cancer drug target.[20] Taken together,
considering the lack of specificity of EN-460, novel probes are required to fully validate whether targeting Ero1L as
a single target is sufficient to induce ER stress and cell death in MM cells while sparing normal cells.
Conclusion
In this study, we show that the FAD containing ER protein Ero1L expression is a prognostic indicator for MM
patients relapsing on therapy, with increased Ero1L expression associated with shorter survival times. We propose
that Ero1L is a putative novel drug target in MM cancers. Others have identified PDI as a potential target for the
treatment of MM.[21] One potential advantage of targeting Ero1L over PDI is that PDI consists of multiple family
members and thus redundancy maybe problematic with respect to emergence of drug resistance. We anticipate that
the lead compounds EN460 and PB-10 can be used to develop more potent and specific inhibitors of Ero1L.
Moreover, the azide functional group handle of PB-10 allows it to be used as a tool for potential development of
further analogues and exploration of SAR using Click chemistry to increase the complexity of the molecule for
design of increased affinity toward ERO1L compared to other FAD containing enzymes. Future studies will be
aimed at developing selective EN460 analogs that do not cross-react with the monoamine oxidase family of
enzymes, which will allow for more robust evaluation of the target in cancers.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1: High Ero1L expression levels are poor prognostic indicator of survival in relapsed MM
patients.
(A) GSE9782, all patients were compared for differences in outcome related to ERO1L expression levels.
Kaplan-Meier estimates were calculated for overall survival in the high (>median ERO1L expression) and
low (<median ERO1L expression) groups. A log-rank test was used to assess significant difference in
outcome. (B) Patients receiving Dexamethasone (n=76). (C) Patients receiving bortezomib (n=188).
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Figure 2: ERO1L inhibitor, EN460, induces apoptosis and ER stress in MM cells.
(A) U266 cells were treated with DMSO (vehicle control) or 25 μM EN460 for 18 h and then subjected to
Annexin V-FITC and propidium iodide (PI) staining followed by flow cytometry analysis of apoptosis.
Data are reported as means ± SD for three independent experiments. (B) U266 cells were treated
with DMSO (vehicle control) and EN460 for 2, 4 and 8 h. Markers for the induction of ER stress
include an increase in phosphorylation of eIf2 alpha, increased ATF4 levels and cleavage of ATF6.
As such we measured the induction of these ER stress proteins following treatment of EN-460.
Following exposure to EN-460 we observed a robust increase in p-eIF2α and a reduction of full length
AYF6. The ATF6 antibody used does not recognize the cleaved product but as shown EN-460
treatment of U266 cells resulted in reduced levels of full length ATF6 consistent with cleavage of the
protein. Surprisingly only a modest increase in ATF4 was detected following treatment with EN-460 in
U266 cells. Equal protein loading is demonstrated by beta actin (n=3 independent experiments).
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Figure 3: Protein-protein interaction (PPI) of Ero1L and PDI.
The docked pose showing the orientation of the two proteins docked to allow for the redox cycling and
electron transfer. Ero1L with the full sequence modeled onto 3AHQ, is shown as silver, and PDI as blue.
The crystal structure of Ero1L the missing sequence is shown in green. The FAD ligand is shown in
atomic colors.
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Figure 4 . Azide modification of EN460 increased efficacy.
(A) Structural formulas of EN460 and PB-EN-10 (an azide derivative of EN460). (B) PB-EN-10 shifts first
derivatives, dF/dT of melt curve compared to vehicle (DMSO). Graph of first derivatives, dF/dT, of
fluorescence intensities of Sypro Orange combined with Ero1α (0.25 mg/mL) and PB-EN-10 (20 μM) or
DMSO. Melting temperatures (Tm) were defined by inflection point in dF/dT (dashed lines). (C) Bar graph
of melting temperatures (Tm) of Ero1α with PB-En-10 (20 μM), EN460 (20 μM), or DMSO. Ero1α/PB-EN10 interaction increased Tm and stability of Ero1α compared to EN460. (D) PB-EN-10 improved inhibition
of hEro1α activity compared to parent compound, EN460. Purified human Ero1α (0.0625 mg/mL)
incubated with increasing concentrations of EN460 or PB-EN-10 with Amplex Red Assay. (E) Graph of
first derivatives, dF/dT of melt curves and (F) Melting temperatures (Tm) of PDI (0.25 mg.mL) were not
altered with the addition of 20 μM of PB-EN-10 or EN460 suggesting the inhibition of Ero1α was not
mediated by PDI. Graphs are represented images of two experiments performed in triplicate.
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Figure 5: Inhibition of FAD containing enzymes activity with EN460.
(A) Ero1L (B) MAO-A (C) MAO-B (D) LSD-1. Each data point is avg. and standard error of fit, with N = 2.
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Figure 6. Enzyme kinetics of EN460 inhibition of Ero1α oxidase.
Ero1α activity was monitored by using an Amplex Red assay. (A) The elevated hydrogen peroxide levels
(intensifying fluorescence) observed with increasing concentrations of purified human PDI protein were
progressively suppressed in the presence of escalating amounts of EN460. (B) Lineweaver–Burk plot of
results in (A) shows EN460 functions as a competitive inhibitor of Ero1α, under these conditions.
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Figure 7: Docking of EN460 in FAD binding pocket of Ero1L.
(A) Hyperactive form of Ero1α (DOI: 10.2210/pdb3AHQ/pdb) was used to determine possible binding of
EN460 in FAD binding pocket with PyMol (Schrödinger). (B)
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Figure 8. Docking of EN460 in binding pockets of other FAD containing enzymes
(A) Monoamine oxidase A (MAO-A) (B) Monoamine oxidase B (MAO-B).
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Figure 9: Docking of EN460 in FAD binding pocket of LSD1.
(A) ligand interaction diagram showing interactions with Val764 and Ala539; (B) docked pose of EN460 in
LSD1.
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Scheme 1: Synthesis of EN460 derivatives.
Pyrazolone (4.2) was synthesized as reported previously. (REF: Org. Lett. 2014, 16, 5060−5063)
Substituted furfuraldehyes (3.1 and 3.2) were synthesized by Suzuki coupling of aryl iodides (2.1(b) and
2.2 (b)) (REF: Org. Lett. 2010, 12, 4217–4219) with furfural-boronic acid (3.1 (b)). (REF: Eur. J. Med.
Chem. 2017, 126, 929–936) Knoevenagel condensation of the substituted furfuraldehyes (3.1 and 3.2)
with pyrazolone (4.2) using catalytic sodium acetate in acetic acid provided EN460 derivatives PB-10 and
PB-11 in 93% and 53% yields, respectively.
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Table 1:
Determination of IC50 value of EN460 and its derivatives, PB-EN-10, PB-EN-11, in U266 and MM1.s
cells. The cell viability was determined by MTT assay after treatment with EN460 and its derivatives for
72 h and then IC50 was calculated. Results are mean ± SD values for 3 independent experiments.
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